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Abstract
Manual segmentation of the metabolic tumour volume (MTV) in positron
emission tomography (PET) imaging is subject to intra and inter-observer
variability. Many PET based automatic segmentation algorithms (PET-
AS) have been proposed as solutions to this problem with machine-learned
techniques showing promise for accurate MTV segmentation. However, no
consensus has been reached on the optimal method for radiotherapy (RT)
treatment planning, with the current American Association for Physcists in
Medicine Task Group 211 and the International Atomic Energy Association
advisory committees recommending that not one single PET-AS can be rec-
ommended for target volume delineation. This project, therefore, aimed to
improve the MTV segmentation of a machine-learned PET-AS methodology
called ATLAAS which has been proposed for standardised MTV segmenta-
tion by Berthon et al in Radiother Onc (2016).
Berthon et al additionally validated the ATLAAS algorithm on diagnostic
PET imaging in Radiother Onc (2017). However, it has not been validated
externally or for the role of MTV segmentation during treatment. Intra-
treatment segmentation is challenging due to reduced metabolic uptake, tu-
iv
mour to background ratio and reduced metabolic volume. Therefore, in this
body of work, the performance of ATLAAS and 151 other PET-AS chosen
from the literature, were evaluated for suitable MTV segmentation in PET
imaging acquired after one cycle of neoadjuvant chemotherapy. This research
resulted in the development of a new training dataset and demonstrated
that ATLAAS can be used as a basis for adaptive radiotherapy and trained
on imaging datasets outside of the original training cohort. However, this
research still demonstrated that the performance of ATLAAS could be im-
proved. Therefore, this led to an investigation into the inclusion of additional
tumour characteristics in the development of the ATLAAS training model, in
order to reduce the impact PET image resolution has on MTV segmentation.
In this research, derived MTVs were compared to “ground truth” volumes
derived from CT imaging. The results presented in this body of work, showed
that interpolating PET imaging to the resolution of the CT image improved
the performance of PET-AS segmentation and improved ATLAAS MTV seg-
mentation by 19% and inclusion of one of the tumour features compactness
one, compactness two or sphericity in the ATLAAS training model improved
MTV segmentation by an additional 3%.
As part of this body of work, the requirement for a standardised PET-AS
method was demonstrated by developing prognostic models, using standard-
ised imaging and tumour features, from the MTV derived by 9 PET-AS
demonstrated by Berthon et al in Phys. Med. Biol (2017) to be promising
for accurate MTV segmentation. This showed how segmentation of the MTV
120-80% Threshold in increments of 10%, Adaptive Thresholding, Region Growing,
K-means Clustering with 2 and 3 clusters, Gaussian Fuzzy C-means with 3 and 4 clusters
and Fuzzy-C means with 2 clusters
v
has a subsequent effect on patient risk stratification with patients changing
risk stratification quartiles dependent upon the PET-AS used to derive the
MTV.
vi
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Chapter 1
Radiotherapy of Cancer
This chapter outlines the aim and structure of this thesis whilst providing
background knowledge into the management of cancer and the challenges
which exist in the delivery of Radiotherapy (RT) treatment. This chapter
also outlines the role of nuclear medicine imaging in RT planning. In the
following section the structure of this thesis is described.
1.1 Thesis Structure
In this thesis, Chapters 1 and 2 provide literature reviews into the RT of
cancer and the segmentation algorithms proposed for use in RT planning.
Chapter 1 described the challenges which exist when delivering RT treat-
ment. However, Chapter 2 describes the numerous algorithms which have
been proposed to solve these challenges. In comparison to Chapters 1 and 2,
Chapters 3, 4 and 5 contain experimental work conducted throughout this
1
project. Chapter 3 evaluates the impact that automated tumour segmenta-
tion has on the development of prognostic models, Chapter 4 evaluates the
performance of 16 automated PET based automatic segmentation (PET-AS)
methods in nuclear medicine imaging acquired during treatment and Chapter
5 investigates improving the performance of a machine-learned segmentation
methodology by using morphological features in the model development. The
final Chapter, Chapter 6, discusses the findings of this project and places
them in context to the current literature and state of the art. Chapter 6 also
describes the potential future work resulting from this project. In the follow-
ing section Positron Emission Tomography (PET) imaging and segmentation
are introduced.
1.2 A brief introduction to PET imaging and
Segmentation
1.2.1 PET imaging
PET is a functional imaging imaging modality which can be used for the
imaging of tumours in the body. Patients are injected with a solution la-
belled with a radioactive source before being placed on a PET scanner. The
information obtained from the PET scanner is then reconstructed into an
image which is human readable. Figure 1.1a image shows a typical PET
image retrieved after patient scanning. The PET image is of the Head and
Neck (H&N) of a patient with a tumour of the H&N and the extent of the
2
disease, due to the increased metabolic rate of the tumour, is visible to the
human eye. PET imaging is described in more detail in Section 1.8.1
1.2.2 Segmentation
Segmentation is the process of dividing an image into different regions. For
example, dividing an image into its background and foreground. In RT plan-
ning PET imaging is segmented in in order to define the tumour as a RT
target. Segmentation of the tumour requires a human user to visualise all of
the images obtained from the PET scanner. When they detect a tumour on
the image, they manually draw a line (contour) around the detectable extent
of the disease. Figure 1.1b shows a PET image which has been manually
contoured based on visual inspection of a PET scan, with the contour dis-
played in white around the tumour. However, segmentation of the tumour
is limited by inter and intra-observer variability. Inter-observer variability
results in two clinicians having differences in the contours they each draw
for the same image. Additionally, intra-observer variability results in a sin-
gular clinician drawing different contours when the same image is visualised
at different time points. Many PET-AS methods have been proposed as
solutions to this problem, however, the application of PET-AS methods in
RT planning is limited by the current lack of inter-comparison and valida-
tion of PET-AS methods [1]. Standardised PET-AS methodologies have
been proposed, however they have not been demonstrated or validated ex-
ternally to the centre that developed the technique. Further, the limited
resolution of 18F-Fluorodeoxyglucose (18F-FDG) PET imaging means that
3
(a) (b)
Figure 1.1: (a) An example H&N PET image reconstructed from information
obtained from a PET scanner. (b) An example contour drawn in white
around the detectable extent of the disease.
the performance of PET-AS methods is potentially limited in comparison to
delineation on conventional imaging modalities. Automatic segmentation of
PET imaging is described in more detail in Section 2
1.3 Thesis aims
The hypothesis of this project is that the performance of the machine-learned
an automatic decision tree-based learning algorithm for advanced image seg-
mentation (ATLAAS) segmentation methodology, for Metabolic Tumour Vol-
ume (MTV) delineation, will be higher in comparison to advanced PET-AS
methods that have been proposed for accurate MTV delineation.
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A project entitled TITAN, was funded by Cardiff School of Engineering and
Velindre Cancer Centre. In Greek mythology Atlas, is a Titan that stood on
the edge of the Earth holding up the sky. Therefore, this project was entitled
TITAN as it aimed to improve the ATLAAS segmentation methodology. The
project aimed at addressing the issues briefly introduced in Section 1.2 and
was carried out as a collaboration between three institutions:
• The Wales research and diagnostic PET imaging centre (PETIC), which
opened in 2010, offers some of the most advanced imaging equipment in
the UK, with a high resolution scanner providing high quality images
for research and clinical purposes. PETIC is operated by Cardiff Uni-
versity in partnership with Cardiff and Vale University Health Board,
and is located at the University Hospital of Wales in Cardiff.
• Velindre Cancer Centre (VCC), located in Cardiff, is one of the largest
specialist centres for non-surgical cancer treatment in the UK, with
over 5000 new patient referrals every year. It boasts high-end equip-
ment, with electron linear accelerators (linacs) enabling advanced RT
procedures, and strong links with the Wales Cancer Trials Unit and
the Wales Cancer Bank for conducting world class research through
oncology trials.
• Cardiff University, Cardiff School of Engineering conducts world lead-
ing research combined with strong links with industry, therefore making
it one of the leading engineering schools in the UK.
Therefore, the aims and objectives of this thesis are:
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• Improve the performance of the ATLAAS segmentation methodology.
• Externally validate the performance of the ATLAAS segmentation method-
ology.
• Investigate the effect of PET-AS methods on the development of prog-
nostic models, therefore demonstrating the requirement for a standard-
ised PET-AS methodology in planning RT.
• Investigate the role and robustness of the ATLAAS segmentation method-
ology for intra-treatment MTV delineation.
• Investigate the impact of morphological features on the performance of
ATLAAS.
1.4 TITAN project novelty & dissemination
Throughout the TITAN project, novel research was disseminated through-
out the research community. The disseminations from the project were 2
first name authored journal papers and 2 co-authored journal papers. Addi-
tionally, research was presented orally at 4 conferences and as posters at 6
conferences. The novelty of the research contained in this body of work is as
follows:
• Demonstrated PET-AS MTV delineation influences the development
of prognostic models.
• External validation of the performance of the ATLAAS segmentation
methodology.
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• Applied PET-AS methods to and compared PET-AS method perfor-
mance in low tumour to background ratio (TBR) scenarios.
• Compared the accuracy of 16 PET-AS methods for intra-treatment
MTV delineation.
• Demonstrated interpolation of PET imaging to a higher resolution,
before MTV delineation, improves the accuracy of PET-AS methods.
• Improved the performance of the ATLAAS segmentation methodology
by including morphological features as classifiers.
1.5 Management of Cancer
Cancer is one of the leading causes of mortality across the world. In 2012,
across the world, around 14 million new diagnoses of cancer and 8.2 million
cancer related deaths occurred. Europe alone experiences an estimated 24.4%
(≈ 341 thousand) of the worlds cancer diagnoses annually and the patients
diagnosed with cancer, in Europe, experienced a mortality rate of ≈ 21.4%
(≈ 175 thousand) [2]. In men, the most common diagnosed cancer sites
include the prostate and lungs. In women however, the lungs and breasts are
among the most common diagnosed cancer sites. The patient cohorts in this
body of work were diagnosed with primary H&N and primary Oesophageal
Cancer (OC).
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1.5.1 Head and Neck Cancer
H&N cancer is the sixth most common diagnosed cancer type worldwide [3]
with a 5 year survival rate of less than 50% [4]. In comparison to the world-
wide rates of incidence, in the UK, H&N cancer accounts for 3% of all new
cases experienced, with a rate of incidence that has increased by 30% since the
early 1990s [5]. H&N cancer is the collective group of cancers consisting of the
anatomical sites of the H&N, including the oropharynx, oral cavity, larynx
and hypopharynx. In the curative setting, RT is a commonly used treatment
for H&N cancer. There is however increasing interest in multimodality ther-
apy including surgery and chemotherapy [6]. H&N cancers are predominately
squamous cell carcinoma (SCC) with 60% of tumours being Human Papil-
loma Virus (HPV) positive [7] with Tumour, Node and Metastasis (TNM)
staging predominately determining H&N cancer prognosis [8]. However, risk
factors such as HPV status and tobacco usage have been shown to be of sig-
nificant prognostic importance [9]. Further, predominant risk factors in the
diagnosis of H&N cancer are alcohol and tobacco consumption [10].
1.5.2 Oesophageal Cancer
OC is the eighth most common [2] diagnosed cancer worldwide with an es-
timated 456,000 new incidences every year. Prognosis in OC is extremely
poor with rates of mortality approximately matching the rates of incidence,
demonstrated by OC having a 1— and 5—year overall survival (OS) rate of
44% and 15%, respectively [11]. Predominant risk factors in OC are alcohol
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and tobacco consumption. A further potential risk factor is ingestion of caus-
tic substances [2]. OC typically presents as SCC. However, other types occur
including Adenocarcinoma, Neuroendocrine and small cell cancer.
1.5.3 Prognostic models
A variety of techniques are used in the management of cancer. Precision
medicine, however, combined with the application of prognostic models aims
to ensure each patient is managed with the most appropriate treatment,
which may improve patient OS [12–15]. Prognostic models aim to charac-
terise each patient’s risk and OS, when treated with a specific treatment,
dependent upon their characteristics. This is known as a patients risk strat-
ification. A patient with a low-risk stratification stratification has a higher
OS in comparison to patients with high-risk stratifications. Whereas, pa-
tients with intermediate risk-stratification have an OS in between high-risk
and low-risk stratifications. By separating patients into risk stratifications,
ineffective therapies can be avoided. Therefore, preventing patients being
treated with unnecessary and aggressive therapies. The avoidance of these
therapies have the potential to improve a patients quality of life. Prognostic
models are developed from clinical information including TNM staging and
radiomic features [16].
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1.5.4 Tumour Node and Metastases Staging
A patients disease progression and therefore prognosis is determined through
the TNM staging of patients. TNM classification aims to separate patients
into groups and throughout this thesis patients were staged using the TNM
7th edition [8]. Primary tumours (T) are categorised according to the fol-
lowing:
• T0: No evidence of primary tumour
• T1a: Tumour invades lamina propria or muscularis mucosae
• T1b: Tumour invades submucosa
• T2: Tumour invades muscularis propria
• T3: Tumour invades adventitia
• T4a: Tumour invades pleura
• T4b: Tumour invades adjacent structures
Lymph nodes (N) are categorised according to the following:
• N0: Node lymph node metastases
• N1: Metastases in 1-2 regional lymph nodes
• N2: Metastases in 3-6 regional lymph nodes
• N3: Metastases in 7 or more lymph nodes
Distant Metastases (M) are categorised according to the following:
• M0: No distant metastases
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• M1: Distant metastases
Based upon TNM staging patients can be classified into stage groups related
to prognosis. Lymph node and distant metastatic disease increases stage
group as shown in Table 1.1.
Table 1.1: Stage groups based upon TNM Staging
Stage Group T N M
Stage 0 T0 N0 M0
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T3 N0 M0
Stage IIB T1, T2 N1 M0
Stage IIIA T4a N0 M0
T3 N1 M0
T1, T2 N2 M0
Stage IIIB T3 N2 M0
Stage IIIC T4a N1, N2 M0
T4b Any N M0
Any T N3 M0
Stage IV Any T Any N M1
1.5.5 Radiomic features
Radiomic features in medical imaging are algorithms applied to an image
in order to extract and quantify information not visible to the naked eye.
For example, the skewness of the histogram. The extraction of radiomic
features is hoped to improve the prediction of a patients OS and therefore
patient outcome; however, studies have demonstrated that there are numer-
ous challenges in the extraction of quantitative features [17]. The selection of
appropriate and significant features for the development of prognostic models
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is of considerable importance because the reproducibility and robustness of
radiomic features is influenced by external parameters including the MTV
delineation method, image reconstruction parameters and radiomic feature
extraction pre-processing steps [18,19].
1.6 Role of external beam radiation therapy
in the treatment of Cancer
1.6.1 History of radiotherapy
Since the discovery of X-rays in 1895, X-rays have been applied in the clini-
cal environment. As early as January 1896, X-rays were used to treat breast
cancer and skin lesions [20]. A lack of understanding of the biological effects
of radioactivity, however, led to poor cancer control rates and high rates of
morbidity [21]. Technological advancements and improvements in the under-
standing and delivery of RT came from a need for improved disease control
and quality of life. Investigations into the delivery of the total radiation
dose, showed the application of external beam radiotherapy (EBRT) as a
fractionated dosage reduced toxicity in H&N cancer compared to delivery of
a single large dose [22]. Further, the development and installation of mega-
voltage linacs in the 1950s led to improvements in the efficacy of treatments
in comparison to the original 200 kilovolt X-rays [21].
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1.6.2 Radiotherapy techniques
As our understanding of how X-rays and ionised rays impacted tumour biol-
ogy, improvements in EBRT, in more recent years, have come from focusing
upon the conformality of the delivered dose as well as multi-modality treat-
ment pathways. Improved understanding has also led to the development of
multiple EBRT techniques, which are outlined below:
• 3D-Conformal Radiotherapy (3D-CRT) delivers a uniform radiation
dose to the tumour, with a specified width, height and depth. However,
in comparison to some other EBRT techniques, 3D-CRT encompasses
a greater amount of healthy tissue. Increased dosage to the organs
at risk (OAR) reduces the efficacy of the treatment and increases the
likelihood of local-regional and local tumour recurrences.
• Intensity modulated radiotherapy (IMRT) delivers a greater radiation
dose to the tumour and a reduced radiation dose to the surrounding
healthy tissue in comparison to 3D-CRT. This improves toxicity lev-
els and improves incidences of local and local-regional reoccurrences.
IMRT relies upon the use of collimator leafs to shape the radiation
beam and reduce toxicity to the surrounding tissue. However, IMRT
is characterised by steep dose gradients which decrease the margin for
error in RT planning [23].
• Image guided radiotherapy (IGRT) makes use of imaging at the pre-
treatment and treatment delivery stage that can lead to improvements
or verify the accuracy of radiotherapy. IGRT encompasses a wide range
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of techniques from simple visual field alignment checks, through to
more complex volumetric imaging that allows direct visualisation of
the radiotherapy target volume and the surrounding anatomy [24].
1.7 Challenges in Radiotherapy Treatment and
Delivery
Accurate targeting of the tumour requires careful planning of a RT beams’
shape and position. RT planning is a time-comsuming process approached
with dedicated software. The software calculates the optimal beam arrange-
ment based upon contour information determined by the planning clini-
cian for the tumour and OAR. Contours are drawn using information from
anatomical imaging, including Computed Tomography (CT) imaging. CT
imaging measures the density of tissue in comparison to water using Hounsfield
units. Figure 1.2 shows a CT scan obtained of the Liver demonstrating the
different tissue densities in the human body. Reference Hounsfield units for
tissue are -1000 for air, 0 for water and +700 for bone tissue. The Liver has
Hounsfield values of ≈ 54-60. Contouring techniques can sometimes be com-
bined through consensus techniques and the registration of imaging. RT plan-
ning requires definition of multiple contours as shown in Figure 1.3 and de-
fined in the International Commision on Radiation Units and Measurements
(ICRU) report number 50 [25] and more subsequent reports [26–28]:
• Gross Tumour Volume (GTV), corresponding to all of the detectable
disease
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• Clinical Target Volume (CTV), an extension of the GTV with a margin
accounting for microscopic disease extension
• Planning Target Volume (PTV), an extension of the CTV accounting
for errors in patient positioning, dose delivery and contouring errors.
Current RT treatments allow for precise RT dose delivery to the target.
GTV delineation, however, has been identified as the largest source of error
in the delivery of accurate RT treatments [29] with results being difficult
to reproduce due to user involvement [30]. Increasingly, PET imaging is
being investigated for providing additional and complementary information
that can be used to improve the performance of GTV delineation in RT
planning [31–38].
1.8 Nuclear Medicine Imaging in Radiother-
apy Planning
There are three different imaging modalities in nuclear medicine imaging.
These are Planar Scinitgraphy (PS), Single Photon Emission Computed To-
mography (SPECT) imaging and PET imaging. Figures 1.4, 1.5 and 1.6 show
example images obtained from each imaging modality. Figure 1.4 shows an
image obtained from a patient scanned using PS. The patient shown in Fig-
ure 1.4 was injected with a radiotracer used for the detection and imaging
of bone tumours. In PS, areas of increased radioactivity are more visible
in the image in comparison to less radioactive areas. Therefore, in Figure
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1.4 the skin is seen as a light colour, whereas the bones are the darker re-
gions. Areas of increased radioactivity in comparison to the imaged tissue
are therefore potentially cancerous due to a tumours increased metabolic ac-
tivity. A patient scanned using a PET scanner is shown in Figure 1.5. In
conjunction with PS, in PET imaging, areas of increased radioactivity are
more visible in comparison to less radioactive areas. In comparison, Figure
1.6 shows an image obtained from a patient scanned using SPECT. The pa-
tient shown in Figure 1.6 was injected with a radiotracer into the vascular
system in order to monitor blood flow (diffusion) in the brain. The bright
(orange) regions of the image indicate increased blood flow compared to the
surrounding area.
PS is the most simplistic imaging modality producing a single two dimen-
sional (2D) image and is mostly used for whole body screening for tumours,
whereas SPECT & PET imaging produce a series of continous 2D images [43].
PET imaging, in comparison to SPECT, has between a 100 and 1000 times
higher signal to noise ratio (SNR) as well as higher spatial resolution [44].
The higher SNR and spatial resolution of PET imaging offers increased di-
agnostic power [43] and in comparison to conventional anatomical imaging
such as CT, PET imaging discriminates between healthy and tumour tissue
with a higher sensitivity (1.1) and specificity (1.2) [34,35,45–50]. Figure 1.5
shows a CT image obtained from patient scanned for lung cancer, anatom-
ical tissue including the liver is visible to the human eye. However, due to
the homogeneous tissue density within organs, tumours within an organ are
difficult to detect.
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TP corresponds to the number of true positives, e.g. the number of people
correctly identified with tumours. FN corresponds to the number of false
negatives, e.g. the number of people with tumours incorrectly identified as
being healthy. TN corresponds to the number of true negatives. e.g. the
number of healthy people without tumours being identified as healthy. FP
corresponds to the number of false positives. eg: the number of healthy
people without tumours identified with tumours.
With the use of nuclear medicine imaging it is therefore possible that patients
with cancer can be diagnosed earlier, as the extent of the disease is more
visible at earlier stages of the disease progression. With earlier diagnoses,
it is possible for patient OS to increase due to less aggressive treatment
pathways being required [38]. The extent of disease detectable on 18F-FDG
PET imaging is known as the MTV.
sensitivity =
TP
TP/FN
(1.1)
specificity =
TN
TN/FP
(1.2)
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1.8.1 PET Imaging physics
As early as the 1950s, the technology behind PET imaging was being re-
searched [51]. The first applications of PET imaging were the modelling
of blood flow and imaging of brain tumours [52, 53]. It was not until the
early 2000s, however, that a complete PET/CT scanner was developed [54].
PET imaging requires the injection of ‘radiotracers’, which are analogues of
biological molecules labelled with positron-emitting radioisotopes, into the
patient. Once patients are injected they typically rest for a period of time,
before being scanned, to allow for the maximal uptake of the tracer in the
tumour before radioactive decay. After waiting for maximal uptake of the ra-
dioisotope labelled tracer in the patient, the patient is placed on the scanner
bed.
During the scanning procedure, positrons are emitted from the tumour and
travel approximately 2 mm before colliding with electrons. At the point
of collision an annihilation event occurs from which two 511 keV gamma
rays are produced [55] as shown in Figure 1.7 on page 30. The two gamma
rays are detected by scintillation crystals made from bismuth germanate,
lutetium oxyorthosilicate or gadolinium silicate [56]. Scintillation crystals
are arranged into blocks around a detector ring and convert the energy from
the gamma rays into light. As the gamma ray hits the scintillation crystal, the
electrons are energised through Compton scatter or photoelectric absorption
processes. As the electron travels further through the scintiallation crystal, it
loses more energy and excites more electrons. As the excited electrons decay
into their non-excited state they give off light. Detector blocks are coupled to
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photomultiplier tubes (PMT)s which convert the light from the scinitillation
crystal into a voltage signal [43]. PMTs and scinitillation crystals may be
interfaced in a couple of ways. A 2D array of crystals may be coupled to 4
PMTs or an array of PMTs may be coupled to a single cut planar crystal [57].
A PET/CT scanner consists of between 20-30 detector rings, each consisting
of thousands of scinitillation crystals. The spatial resolution of PET imaging
is dependent upon a comprimise between the number of scinitillator crystals
and PMTs. Increasing the number of crystals increases the SNR, however,
the physical size of the PMT limits the spatial resolution [43].
Compton Scattering
Compton scattering is an interaction between a photon and a loosely bound
outer-shell orbital electron of an atom. Where the energy of the incident pho-
ton greatly exceeds the binding energy of the electron to the atom, the inter-
action looks like a collision between a photon and a “free” electron [58].
The photon in Compton scattering is deflected through the scattering angle
Θ and part of the photons energy is transferred to the “recoiling” electron.
Therefore, the photon loses energy. The scattered photon energy is related
to the angle Θ which the photon was deflected by (1.3).
Esc =
E0
1 + (
E0
0.511
)(1− cos θ)
(1.3)
E0 is the energy, in MeV, of the incident photon and Esc is the energy, in
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MeV, of the scattered photon. The energy of the recoiling electron Ere is the
difference between the incident and scattered photon energies (1.4).
Ere = E0 − Esc (1.4)
The energy imparted to the recoiling electron ranges from ≈ 0 for a scattering
angle θ of ≈ 0 degrees. The maximum amount of energy transferred to the
recoiling electron occurs in backscattering events where the scattering angle
θ is 180 degrees. During backscattering events the scattered photons also
have a minimum resulting energy due to imparting the maximum amount of
energy to the electron.
Photoelectric absorption
Photoelectric absorption occurs at the lower photon energies [59]. In compar-
ison to the energy of the incident photon in Compton Scattering, the energy
of the incident photon in photoelectric absorption, is equal to or slightly
greatly than the binding energy of the electron to the atom. The incident
photon interacts with an inner-shell electron which absorbs the energy of the
incident photon. The transferred energy is greater than the binding energy
of the electron causing it to be ejected from the atom [59]. The remaining
energy is converted into kinetic energy allowing the ejected electron to travel
through matter.
Ejected electrons are emitted at all angles. However, the angle of emission is
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smaller the higher the energy of the incident photon. As the ejected electron
travels through matter the kinetic energy is dissipated in the atoms of the
matter, until they are brought to rest. The vacancy left in the inner electron
shell, by the ejected electron, is filled by an outer-shell orbital electron by
electron transition. This effect cascades throughout the outer-shells with the
vacancy left in one shell being filled by further outer-shell electrons.
1.8.2 Attenuation correction and Hybrid PET/CT Scan-
ners
Gamma rays produced from concentrations of radiotracer located in the cen-
tre of the body have to pass through more tissue compared to gamma rays
produced closer to the skin. The gamma rays produced from deeper in the
body are attenuated more, therefore attenuation correction is required for
accurate quantification of the radiotracer uptake. Before the development
of hybrid PET/CT scanners attenuation correction was performed using a
transmission based callibration. However, the SNR and spatial resolution of
the CT-based attenuation data is superior to that of the transmission based
callibration and is faster to acquire [43], which led to the development of hy-
brid PET/CT scanners. A further advantage of a hybrid PET/CT scanner
is that scans are acquired at the same time, with the patient in the same po-
sition. Therefore, the registration of functional and anatomical information
is possible [56] allowing for improved differentiation between abnormal and
normal radiotracer uptake.
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1.8.3 PET tracers
PET radiotracers are positron emitters with short half-lives compared to
other emitters, including Iodine-124 (124I) and Manganese-52 (52Mn). 124I
and 52Mn have half-lives of 102.2 hours and 134.2 hours respectively [60].
Common emitters are Flourine-18 (18F), Carbon-11 (11C), Oxygen-15 (15O),
Nitrogen-13 (13N) and Rubidium-82 (82Rb). The labelling of a radionu-
clide with analogues of biological molecules to create a radiotracer allows
for the depiction of different biological processes to be obtained from a PET
scan. 18F-FDG is a glucose analogue which relies upon a tumours increased
metabolic activity, in comparison to surrounding healthy tissue, for the de-
picting of the tumour tissue. 18F-FDG has a half-life of 110 minutes and is
a positron emitter producing a 511 keV gamma ray after annihiliation [57].
Patients are typically injected with a fixed dose of ≈ 350 MBq or a dose of ≈
4 MBq of 18F-FDG/kg and rest for ≈ 60-90 minutes before being scanned. In
comparison 18F-FDG, 11C-Choline (11C-Ch) relies upon a tumour’s increased
choline transport properties. Therefore, 11C-Ch allows for the depiction of
these tumours in areas 18F-FDG is unsuitable, due to naturally high-levels
of metabolic activity [61]. 11C-Ch has a half-life of 20.5 minutes and is a
positron emitter producing a 511 keV gamma ray after annihilation. Fur-
ther to taking advantage of the increased properties of tumours, radiotracers
such as 15O, 82Rb and 13N can be used for the monitoring of blood flow and
also in perfusion studies. 15O has a half-life of 2 minutes, whilst 13N and
82Rb have half-lifes of 10 minutes and 75 seconds respectively. 13N and 15O
are solely positron emitters producing 511 keV gamma rays; however, 82Rb
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is a positron emitter and additionally uses electron capture decay processes
which produce 511 keV and 777 keV gamma rays respectively.
1.8.4 Sinogram
Detected annihilation events are stored in a Sinogram. For each event, a line
known as the Line Of Response (LOR) can be drawn between the detectors
as shown in Figure 1.8a on page 30. Where A, B, C and D are the LOR
drawn between pairs of detectors for detected events and X is the centre of
the detector ring gantry. Each events LOR is plotted as its angular orienta-
tion around the detector ring (from -90°through 0°to 90°) against the LOR
displacement from the center of the detector ring to generate the Sinogram as
shown in Figure 1.8b on page 30. Where A, B, C and D are the corresponding
LOR from Figure 1.8a.
1.8.5 PET Image Reconstruction
PET images are reconstructed into visual representations from the Sinogram
obtained from the PET scanner. A variety of techniques exist for reconstruct-
ing PET Sinograms [43], including back-projection, filtered back-projection
and iterative reconstruction techniques. Additionally Time of Flight (TOF)
information recorded during acquisition of the of the Sinogram can be used
during the reconstruction process to improve imaging contrast and reduce
noise. Figure 1.9 demonstrates noise present in a PET image as well as a
PET image denoised using a median filter. Two areas of noise in the PET
23
image are shown in red and blue. The noise is represented by darker regions
in areas of no to little uptake and are typically a singular voxel. When a
denoising filter is applied to the image, the heterogeniety is reduced within
the red and blue circles.
Back-projection
In back-projection, a reconstruction matrix resolution is chosen and LOR are
traced back along through the grid. The counts from each LOR are added to
the counts of the preceding back-projected data, resulting in a back-projected
image of the original object [57]. Simple back-projection techniques are lim-
ited by the blurring of the original object; however, blurring is decreased with
increased distance from the original object. Blurring is therefore considered
to be spill over from the object into neighbouring voxels.
Filtered Back-projection
Filtered back-projection techniques take advantage of the knowledge that the
blurring of a back-projected image decreases with increased distance from
the original object by applying filters to the acquired data. Application
of a one dimensional convolution filter to the data, before back-projection,
results in an image which closely approximates the original object. Ad-
ditionally, Fourier transform methods complement filtered back-projection
techniques by transforming the spatially projected data into the frequency
domain. Transforming the data into the frequency domain allows for fre-
quency domain filters to be applied to the image.
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Iterative Reconstruction methods
Iterative reconstruction differs from back-projection based methods by us-
ing an iterative process and estimating an initial image. The projections for
the initial estimated image are computed and compared against the mea-
sured projections in the Sinogram obtained from the PET scanner [43]. A
correction factor is then applied to projections in order to generate a new
Sinogram. The new Sinogram is then back projected to generate a new esti-
mated image for input into the next iteration. Iterative reconstruction using
maximum-likelihood expectation maximisation (MLEM) is a computation-
ally expensive process, requiring hundreds of iterations of each projected view
before achieving acceptable agreement between the estimated image and the
measured projected data. ordered subset expectation maximisation (OSEM),
however, reduces the computation time by grouping the angular projections
into subsets and MLEM is performed on a subset rather than each projection
in the subset.
1.8.6 DICOM Imaging format
Reconstructed PET images are exported from the scanner to the Digital
Imaging and Communications in Medicine (DICOM) file format before be-
ing transferred to the picture archiving and communications system (PACS).
DICOM is the standard for the communication and management of medical
imaging information and related data [62]. The DICOM standard facilitates
interoperability and compatibility of medical imaging equipment by specify-
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ing network communications, the syntax and semantics of commands, media
storage services as well as a file format and directory structure. A basic file
structure for the DICOM standard is shown in Figure 1.10 on page 32.
1.9 Chapter 1 Overview
H&N & OC are two of the most commonly diagnosed cancers across the
world today, with RT treatment being commonly used in the curative and
palliative setting. Improvements in the technology behind RT have led to in-
vestigations in the con-formality of the delivered RT dose and multi-modality
treatment pathways. Delineation of the GTV, however, has been identified
as the largest source of error in accurate RT delivery. Therefore, PET imag-
ing has been investigated for providing complementary information to aid
in accurate GTV delineation. However, the low spatial resolution of PET
imaging combined with complex biological uptake of the radiotracer means
delineation on PET imaging is subject to inter and intra-observer variability
and is a time consuming process. These combined challenges drive the inter-
est in the need for semi-automated and automated delineation of the tumour
on PET imaging. The following chapter introduces PET-AS algorithms and
compares the methods that have been proposed in the literature.
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Figure 1.2: CT scan of patient. a) Air has a density of -1000 Hounsfields,
b) Liver, has a density of ≈ 54-60 Hounsfields and c) Bone has Hounsfield
values of +700.
Figure 1.3: The GTV corresponds to all of the detectable disease. Whereas,
the CTV is an extension of the GTV, which incorporates all of the GTV
whilst accounting for microscopic disease extensions. An additional expan-
sion of the CTV is required to account for errors which occur during radio-
therapy planning and delivery.
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Figure 1.4: A planar scinitgraphy obtained from a patient injected with a
radiotracer designed for the imaging and detection of bone tumours [39].
Areas of increased metabolic activity / radioactivity are darker and more
visible in comparison to less metabolically active tissue.
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(a) PET scan (b) CT scan
Figure 1.5: (a) PET showing heterogeneous uptake of the radiotracer in
the liver. The more visible areas have increased metabolic uptake and are
therefore potentially cancerous and b) CT imaging showing homogeneous
tissue density values obtained from the same patient [40, 41]
Figure 1.6: SPECT images obtained from a patient injected with a radio-
tracer designed for the monitoring of diffusion of blood in the brain [42].
Areas which are more visible (orange) indicate increased blood flow.
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Figure 1.7: The collision of an positron emitted from 18F-FDG and an elec-
tron resulting in an annihilation event and generation of gamma rays detected
by the PET scanner.
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(b) Sinogram of four lines of response de-
tected by a PET scanner.
Figure 1.8: Lines of response and the resulting generated Sinogram.
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(a) Original PET scan
(b) Denoised PET scan
Figure 1.9: (a) PET showing heterogeneous uptake of the radiotracer. Two
areas of noise in the PET image are shown in red and blue. The noise is
represented by darker regions in areas of no to little uptake and are typically
a singular voxel. (b) A median filter is applied to the PET image to reduce
noise present in the obtained image.
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…
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Figure 1.10: DICOM standard file format.
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Chapter 2
Segmentation of PET
PET-AS methods potentially offer a more reliable MTV delineation process,
which reduces intra-observer and inter-observer variability [37]. Thereby,
this allows for the standardisation of MTV delineation across multiple cen-
tres [63], which is critical in multi-centre clinical trials. Multiple segmenta-
tion algorithms and methodologies have been published and recommended
for use in clinical practice [35,64–72]. There has been no recommendation or
consensus, however, on a single segmentation method for use in the clinical
environment [1] as the proposed PET-AS methods have been shown to per-
form differently when applied to PET images with different conditions [33].
The PET-AS methods investigated throughout this body of work are sum-
marised in Table 2.1. The following section defines classifications for the
proposed PET-AS methods based upon their implementation, approach and
level of automation.
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Table 2.1: Name and description of PET-AS methods used in this study,
with references of published work using similar segmentation approaches
Algorithm Description Key References
AT 3D Adaptive iterative
thresholding, using back-
ground subtraction
Jentzen et al [67], Drever et al [66]
RG 3D Region-growing with au-
tomatic seed finder and
stopping criterion
Day et al [68]
KM 3D K-mean iterative clus-
tering with custom stopping
criterion
Zaidi and El Naqa [35]
FCM 3D Fuzzy C-mean itera-
tive clustering with custom
stopping criterion
Belhassen and Zaidi [71]
GCM 3D Gaussian Mixture Mod-
els based clustering with
custom stopping criterion
Hatt et al [72]
WT Watershed Transform-
based algorithm, using
sobel filter
Geets et al [69], Tylski et al [70]
2.1 Classification of PET-AS methods
PET-AS methods vary in implementation design, from intuitive threshold
based segmentation methods [32], which include in the resulting tumour vol-
ume all voxels with an intensity higher than a single threshold value, to
advanced machine-learned approaches [65]. Further, PET-AS methods differ
in levels of automation, from being fully automated to semi-automated re-
quiring user input. Within these, PET-AS method implementations can vary
using differing pre and post-processing steps. Therefore, PET-AS methods
can be classified in a variety of ways [1]:
34
• The segmentation algorithm employed and its assumptions and com-
plexity.
• Level of pre and post-processing steps.
• Automation level.
The classification of PET-AS methods based upon image segmentation ap-
proach is a commonly used practice. This classification process relies upon
comparing the statistical approach, clustering methodology, simplicity or
complexity of the PET-AS algorithms.
A second classification approach compares PET-AS methods based upon
the pre and/or post-processing steps used in the specific implementation of
the PET-AS algorithm. PET-AS algorithms, however, are typically applied
to raw PET data that have not been pre-processed. Optionally, de-noising
filters may or may not be used in a PET-AS algorithms implementation.
Within this classification approach, further classifiers are the use of phantom
acquired data to optimise the PET-AS algorithm, as well as the requirement
of image databases to develop statistical models for MTV delineation.
Classifiying PET-AS algorithms based upon the level of automation requires
the division of the MTV delineation into two different steps [73]. These pro-
cesses are the identification of the tumour location and then the delineation
of the MTV. Dependency of MTV delineation on operators, through the
identification of the tumour location, requires operators to have specific ex-
pert knowledge of 18F-FDG PET, MTV delineation and the diagnosed cancer
type. Therefore, the majority of PET-AS algorithms rely upon identification
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of the tumour location by a user defining a volume of interest (VOI). The
PET-AS method is then applied within this defined VOI. This is classed
as the standard delineation process and therefore the majority of PET-AS
algorithms are regarded as semi-automated, due to the need for human inter-
action. Other proposed algorithms rely upon the identification of the tumour
location after application of the PET-AS method to the PET image [71] or
the manual definition of the area defined as the background uptake in a
PET image. Additionally, some PET-AS methods and algorithms require
the definition of seed points, within the tumour location, from which the
segmentation algorithm is initialised [74].
2.2 PET-AS method implementations
2.2.1 Fixed and adaptive threshold algorithms
In the most simplistic threshold-based PET-AS method, the threshold value
is defined by the user of the computer. The threshold value can be defined as
a single absolute intensity value, or as a percentage of the maximum intensity
within the image (see Equation 2.1). I(i,j) is the value of the image at point
i, j and T is the user defined threshold. Output(i,j) is the final value in the
output image at point i, j. Defining the threshold as a percentage allows for
an image, tumour and patient independent MTV delineation process. This
independence is further enhanced when an image voxel value is converted
to a Standardised Uptake Value (SUV) (see Eq. 2.2). The injected activity
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(ID) corresponds to the amount of activity injected corrected for radioactive
decay between injection and image acquisition. The measured activity (Cimg)
is the activity on the acquired PET image, the body weightBW of the patient
being expressed in kg.
Output(i,j) =

0, if I(i,j) < T
1, if I(i,j) >= T
(2.1)
SUV (t) =
Cimg(t)
ID/BW
(2.2)
However, the maximum SUV (SUVmax) of
18F-FDG PET imaging has been
found to be subject to noise [75], therefore thresholding based upon a per-
centage of the peak SUV (SUVpeak) has been proposed as being a more robust
methodology [76]. The SUVpeak of a PET image is defined as the mean up-
take in a 1 cm3 sphere centred around the SUVmax of that PET image. For
multiple equivalent SUVmax values, the maximum SUVpeak is selected.
Adaptive thresholding techniques define the threshold relative to the differ-
ence between the SUVmax or SUVpeak of the MTV and the mean intensity
of a region defined as the background. Adaptive thresholding techniques are
typically iterative processes that assume the biological uptake of the radio-
tracer in comparison to the background uptake is distinctly bi-modal and
relatively homogenous. Therefore, an appropriate threshold can be found by
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minimising the change in the tumour volume in comparison between one iter-
ation and the previous iteration. The definition of the background, however,
is implementation dependent [67,77–79].
Whilst simple in implementation, thresholding methods have been shown to
lack robustness [37] and are subject to the thickness of phantoms walls [77,80].
The performance of thresholding methods has also been shown to correlate
with the SUVmax [32] and the volume of the tumour [81]. These dependencies
require operators to have image and patient specific information, combined
with expert training to accurately delineate the MTV when using threshold-
based PET-AS methods.
2.2.2 Gradient segmentation
Gradient-based segmentation algorithms are based upon finding contours
which naturally transition areas with high biological uptake and areas with
low biological uptake. If the PET image is visualised as a height map, the
changes in color, intensity or texture correspond to the crests and troughs of
the image. Qualitively, edges occur at the boundaries between regions of dif-
ferent color, intensity or texture [82]. The edges can be detected by gradient-
based threshold approaches, region-growing techniques using gradient-based
thresholding, watershed transform methods which use flooding-based tech-
niques [70] and active contouring [83].
In Watershed segmentation, the image is considered to be a topographical
map, for which minima and maxima can be defined. The map is flooded from
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the minima until a singular maxima is remains. Figure 2.1 demonstrates the
different stages of Watershed segmentation. Local minima are selected in
the height map (orange points) and the image is flooded from the minima.
The flooding continued until a singular maxima (red points) is left and the
resulting watershed (black arrow) is considered to be the final contour.
In active contouring, contours are iteratively deformed and attracted to the
crests of an image until a stable contour is reached. In Figure 2.2, an initial
loose active contour (red line) is defined around the obect to segment (blue
T). The active contour is attracted to the change in image intensity between
the white background and the object to segment. The final segmentation is
reached once the active contour is considered stable. Deformations of the
contours can be influenced by image and user guided forces such as anchor
points.
An advantage of gradient based methods, in comparison to threshold meth-
ods, is that the uptake distribution does not need to be homogeneous along
the contour. However, gradient-based methods depend upon the precision of
the gradient information, which is influenced by spatial resolution [1]. Addi-
tionally, computation of the gradient map amplifies noise in the PET image.
Noise is seen as singular voxels with areas of radiotracer uptake, surrounded
by low uptake. Therefore, due to the well defined difference between the noise
and the surrounding uptake, the boundary between them is determined to
be an edge, when computing the gradient map. Therefore, de-noising algo-
rithms should be applied as long as the spatial resolution of the PET image
is not decreased.
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2.2.3 Region growing
Region growing techniques avoid the generation of disconnected contours on
slices by including in the MTV, voxels in the neighbouring region which sat-
isfy a similarity criteria. The first region is grown from the SUVmax, SUVpeak
of the image or an operator selected seed point. Voxels are included within
the grown region based upon statistical properties such as the mean uptake
and the Standard Deviation (SD), confidence intervals, textural properties
or whether the neighbouring voxels are within a specified threshold range.
Voxels included based upon similarity to a threshold range are considered
to be connected threshold algorithms. Further to differing inclusion criteria,
differing stopping criteria can be implemented. Stopping criteria may include
the total number of voxels included as the tumour volume, the number of
iterations reached or the difference between the mean background definition
and the mean uptake within the tumour volume delineation. Definition of
the inclusion criteria and stopping criteria can require the definition of hyper-
parameters set by the user; however, optimisation of the hyper-parameter is
not possible for all objects [68].
2.2.4 Statistical
Statistical image segmentation aims at classifying voxels within an image into
different clusters (unique memberships) and regions based upon the statisti-
cal properites of these clusters and regions. This is achieved by probability
calculations and estimations. The number of clusters is typically defined
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by the operator. Further to this, clustering classification can be binary
(background or tumour) as well as probability values. Definition of clus-
tering memberships has been investigated by a number of groups [35,71,84].
However, the number of clusters to classify is operator and implementation
dependent.
2.2.5 Consensus Techniques
Consensus techniques, including the simultaneous truth and performance
level estimation (STAPLE) [85] algorithm and majority vote (MJV) [86]
techniques, are based upon the definition of multiple contours by individ-
ual PET-AS methods. PET-AS method generated contours are combined
based upon statistical probabilities [64] with the aim of minimising the limi-
tations of each segmentation method and maximising the advantages of each
one.
2.2.6 Machine learning
Machine-learning approaches to MTV delineation require a learning task
consisting of the discrimination of biological tracer uptake within a tumour
volume and the background. Learning techniques can be divided into two
categories: supervised and un-supervised learning. Supervised learning esti-
mates a mapping from labelled samples which make up the training dataset.
Samples are typically labelled manually. In unsupervised learning input sam-
ples are used to generate a map; however, their labels are not provided. In
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the learning stage, the development of the optimal model with the optimal
features is sought. This is followed by a validation stage, which aims to
quantify the performance of a model on data outside of the training stage.
A variety of machine-learning and classification approaches exist.
Decision Trees
Decision tree (DT) techniques develop a set of rules from a pre-defined set
of features by the development of questions. This results in tree-like struc-
tures, with leaf nodes representing the final classification of the object being
identified. A limitation of DT approaches is that deep and complex trees can
be the result of overfitting. Overfitting of the model, to the training data,
results in limited performance for the model on data outside of the train-
ing model. In complex DTs it is therefore preferable to prune the resulting
model, to improve the model performance and for the generalisation of the
model.
Random Forest
Random forests are similar to DT approaches. However, they result in the
development of multiple DTs from features selected randomly from a set of
pre-defined features. The classification result is then the averaged result from
all of the DTs that were developed as part of the training step. Due to the
development of multiple DTs, random forest approaches are not as easily
subject to the overfitting of the model. However, this results in an algorithm
which is slow and unsuitable for real-time analysis. The number of DTs
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developed as part of the forest are defined as a hyper-parameter. Typically,
the more trees developed, the more accurate the model. Further, Random
Forests require a larger number of features compared to DTs.
Support Vector Machines
A Support Vector Machine (SVM) is a type of machine learning algorithm
which plots data points from provided features into a n-dimensional space
where the number of dimensions matches the number of features. The SVM
finds the hyper-plane (boundary) which segregates the classes. The hyper-
plane segregating the classes is chosen based upon the performance and mar-
gin of the hyper-plane to the classes of data. SVMs are robust to outliers,
due to hyper-planes being chosen based upon performance. If data classes
are not segregated by a hyper-plane an additional feature and dimensionality
is added to the model. The hyper-plane is found from the transformation
of the data in this additional space and then transformed back to the origi-
nal number of dimensions. The reliance of hyper-planes in SVM means the
performance of the method in high noise data is limited.
Deep Learning
Deep learning requires the training of a model consisting of many layers which
use the output from previous layers as input. For example, a convolution
neural network consists of fully connected neural networks with alternating
layers of convolution and max-pooling layers. Max-pooling layers sample the
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data in order to reduce data dimensionality. Therefore, allowing for assump-
tions to be made about features contained in the sub-regions to be binned
and to provide an abstract representation of the data. Investigations into the
role of machine-learning based segmentation methodologies and PET imag-
ing are limited due to the higher level of complexity required in comparison to
the methods described previously. Additionally, deep learning investigations
are typically limited to Magnetic Resonance (MR) or CT-based studies [17].
For more information see the book Deep Learning written by Goodfellow et
al [87].
2.3 PET-AS Comparison
Comparison of the performance, robustness and suitability of the mutiple
PET-AS methods that have been proposed for MTV delineation is challeng-
ing, due to the proposed methods being validated in differing anatomical
sites and on differing PET imaging datasets [17]. Comparison studies typ-
ically compare the results of PET-AS MTV delineation against the ground
truth from spherical phantom inserts or manually defined contours rather
than histopathological samples [33,48,74,86,88]. Tylski et al [74] compared
4 threshold methods and a model-based method in 17 Spheres and 41 non-
spherical simulated tumours. However, the results of the PET-AS MTV
delineation weren’t compared in clinically acquired scans (manual contours
or histopathological data). Phantoms are common tools for analysing the
sensitivity, noise and spatial resolution of the PET scanner in the clinical
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environment [1], therefore are more readily available for comparison studies.
A limitation of using phantom based PET scans for the validation of PET-
AS methods is that they do not represent realistic tumours, due to using
homogeneous uptake on a homogeneous background. Adequate validation
of a PET-AS method on realistic uptake distributions can only be achieved
using synthetic simulated PET scans or clinically acquired PET scans with
histopathological measurement of the tumour. However, the number of stud-
ies comparing the result of PET-AS MTV delineation in synthetic simulated
tumours with known ground truth contours is limited [65,74].
Further, it is challenging to compare methods from the literature alone as
the proposed PET-AS methods have been developed on and validated in
differing PET imaging datasets too. Berthon et al [65] proposed a segmenta-
tion methodology called ATLAAS, which was based upon the application of
machine-learned DTs to select the most appropriate segmentation method-
ology for the delineation of the MTV. The DTs are developed from known
factors which have been shown to effect the delineation of the MTV and in-
clude the TBR and volume (mL). They evaluated their method in 85 phan-
tom and printed sub-resolution sandwich phantoms. In an additional study,
ATLAAS was validated on 20 clinical diagnostic H&N PET scans [36]. In
both studies, ATLAAS was not compared to histopathological data. Geets
et al [69], Belhassen et al [71], Dewalle-Vignon et al [89], Abdoli et al [83]
all validated their proposed PET-AS method in a common cohort of seven
patients obtained from a patient cohort of nine patients [46]. In comparison,
Day et al [68] proposed a 3D region-growing method, which performed bet-
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ter than fixed thresholding schemes on 18 rectal and anal cancer patients;
however, they cautioned it should be used as a starting point for MTV de-
lineation in order to reduce intra and inter-observer variability. Further to
this, Hatt et al [72] developed and validated the Fuzzy Locally Adaptive
Bayesian (FLAB) method, based on a fuzzy clustering scheme incorporating
an expectation maximisation step. The performance of FLAB was evalu-
ated with spherical fillable phantom data and more complex simulated data.
FLAB showed high performance compared to thresholding and other clus-
tering methods, especially for small objects. In a comprehensive comparison
study, Berthon et al [33] evaluated the performance of 8 PET-AS methods
in sixteen non-spherical phantom inserts. These methods, however, were not
compared in clinical data with or without histopathological specimens or
simulated PET data. In the study, it was found that each of the proposed
PET-AS methodologies perform differently under different conditions.
The limited number of participants in PET studies and in the validation
of the proposed PET-AS algorithms limits the statistical power of the re-
sults obtained in studies [36, 46, 68, 69, 71, 83, 89]. This, combined with the
knowledge that PET-AS methodologies perform differently under differing
conditions (as previously mentioned) resulted in the findings of the Amer-
ican Association for Physicists in Medicine (AAPM) Task Group No 211
report [17], which state that no single PET-AS method can be recommended
for realistic target volume delineation in all cases. The AAPM report also
states that machine-learned PET-AS methodologies are showing promise for
accurate target volume delineation. Further to the AAPM Task Group No
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211 report, the current recommendations of the International Atomic En-
ergy Agency (IAEA) is that it is difficult to recommend a single PET-AS
method for accurate MTV delineation [31]. The following chapter aims to
highlight how the application of PET-AS algorithms in the clinical environ-
ment can potentially impact patient OS, thus demonstrating the need for a
standardised PET-AS algorithm.
2.4 ATLAAS
ATLAAS [65] is a predictive segmentation model, incorporated into the com-
putational environment for radiotherapy research (CERR) [90] software pack-
age developed in Matlab. CERR is open source software that was developed
at the university of St Louis (Michigan, USA) and is currently maintained
at the Memorial Sloan Kettering Cancer Centre (MSKCC) in New York
(USA). ATLAAS is designed to select the most accurate PET-AS method
for the optimal segmentation of a given PET image. The most appropriate
segmentation method is chosen from a list of advanced PET-AS methods
and algorithms which have been built into the system. When ATLAAS is
applied to a PET image, ATLAAS computes for each PET-AS algorithm
its predicted performance using a number of parameters extracted from the
target PET image. Performance is quantified as the predicted dice similarity
coefficient (DSC) as shown in Equation 2.3. DSC is defined as twice the
intersection of X and Y , divided by the union of X and Y , where X is the
ground truth contour and Y is the PET-AS contour. The prediction is done
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using a model consisting of DTs built during the training stage of ATLAAS.
The training model is built on a large dataset of PET images with tumour
parameters varying within a defined range. The work flow for the develop-
ment of the training model and application of the training model to a PET
image is shown in Figure 2.3.
DSC =
2|X ∩ Y |
|X|+ |Y | (2.3)
ATLAAS is based upon the principle that differing PET-AS methods may
be more adequate than others for the delineation of different lesions [65] as
clinical lesions can show a variety of patterns, from homogeneous uptake to
highly heterogeneous uptake. Further, clinical lesions may incorporate local
hot spots or necrotic areas. Previous work by Berthon et al [65] identified the
following tumour and PET image characteristics as classifiers for PET-AS
performance:
• Volume (mL): target object volume.
• Tumour to background ratio peak: Ratio between the target object’s
SUVpeak, calculated as the mean value in a 1 cm
3 sphere centred on the
SUVmax in the target object, and the background SUV, calculated as
the mean intensity in a 0.5 cm thick extension of the object contour.
• Number of discrete intensities (NI): a regional texture feature related
to the intensity distribution in the target object.
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Additional parameters may be defined by a user, known as hyper-parameters,
to inform the development of the statistical model. Potential hyper-parameters
for ATLAAS include the lymph node size, the number of involved lymph
nodes, the total number of distant metastases as well as patient character-
istics including weight and age. ATLAAS is designed to have limited user
interaction and with no prior knowledge of the PET other than the primary
tumour location, therefore hyper-parameters are not used in the development
or application of the statistical model.
The following PET-AS methods with different approaches to segmentation
have been included in the ATLAAS training model by Berthon et al [65]
• Adaptive iterative thresholding (AT)
• K-means (KM) with 2, 3 and 4 clusters
• Gaussian Fuzzy C-means (GCM) with 3 and 4 clusters
• Watershed Transform (WT)
2.4.1 Training model development
For each of the included PET-AS methods, a DT is developed from a training
dataset. The ATLAAS training dataset is developed using the PET Simula-
tor of Tracers via Emission Projection (PETSTEP) simulator [91], which is
incorporated into CERR. PETSTEP simulates PET scans using a CT image
and a 18F-FDG background uptake map in order to simulate a PET image
tumour from contours defined by a user. The ATLAAS training dataset was
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generated based on PET/CT data from a fillable phantom. Tumour objects
with a range of characteristics relevant to clinical situations were added to
the background of the phantom. The training dataset consists of 100 spher-
ical tumour objects modeled for volume and maximum uptake values in the
range 0.5 ml-50 ml and 4000 Bq ml-1-40000 Bq ml-1 respectively [65].
2.4.2 Application of ATLAAS training model to FDG
PET imaging
The delineation of the MTV on a PET image, for which the ground truth
(GT) contour is unknown, requires the estimation of the parameters incor-
porated into the developed ATLAAS training model. Estimated parameters
are acquired from an estimation of the MTV, which is delineated by applying
a PET-AS algorithm to the PET image. Estimated tumour characteristics
are used as input to the DTs, which output the predicted DSC for each
PET-AS algorithm included in the training stage of ATLAAS. The PET-AS
method with the highest predicted DSC is then used to delineate the final
MTV.
Region of Interest definition
For accurate estimation of the MTV, the definition of a region of interest
(ROI) is required. A ROI limits over-contouring of the estimated MTV,
allows avoidance of areas of erroneous uptake as well as improving estimation
of the training model parameters. A variety of approaches exist for the
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definition of the ROI:
• Manual definition requires a user to select which voxels to investigate
as potentially being the tumour. This is typically done by “painting”
the ROI on the PET image. This process can be time consuming and
has the same limitations as manual definition of the MTV.
• Existing contour expansion; if a contour has been pre-defined due to
being involved in a retrospective study or RT planning, it is possible to
expand this contour by a user defined measurement to use as the ROI.
• Semi-automated definition of the ROI typically requires the user to
place a sphere or cube of a user defined size around the area to de-
lineate. More advanced semi-automated processes exist, in which the
user defines a limited number of seed points in the saggital, axial and
transverse planes. Seed points are converted to a spheroid around the
centre of mass, which AT is then applied to. The resulting delineation
is expanded. The advantage of this more advanced process is a re-
duced time to define the ROI as it requires only the definition of two
seed points, and a ROI which is clinically relevant to the data in the
PET scan is generated allowing for the avoidance of contouring in areas
of erroneous uptake.
This chapter has discussed the multitude of PET-AS algorithms that have
been proposed for accurate MTV delineation, from simple threshold-based
techniques to more advanced methodologies; including the development of
decision trees from a 18F-FDG PET based training dataset. The follow-
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ing chapter aims to demonstrate the impact MTV delineation has on a pa-
tient’s OS and risk stratification, thereby potentially affecting their quality
of life.
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(a)
(b)
(c)
Figure 2.1: a) The first stage of Watershed segmentation. The image is
considered as a topographical height map and local minima (orange points)
and maxima (red points) are defined from which flooding of the height map
starts. b) From the minima selected in the image, the image is flooded
until a singular maxima is left. b) The resulting watershed (black arrow) is
considered to be the final image contour and segmentation.
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(a) (b)
(c) (d)
Figure 2.2: a) The first stage of active contouring is to define a loose contour
(red line) around the object to segment (blue T). b) The defined contour is
attracted to changes in image intensity. c) The active contour is continuously
modified until it reaches a stable state. d) The final segmentation once the
active contour has reached a stable state.
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Figure 2.3: The ATLAAS training model and application workflow.
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Chapter 3
Impact of metabolic tumour
volume segmentation on
patient overall survival
OC is the eighth most common [2] diagnosed cancer worldwide, with ex-
tremely high rates of mortality. It is hoped that the development of prognos-
tic models, combined with precision medicine, may improve the patient rate
of mortality from 1— and 5— year OS rates of 44% and 15% respectively [11].
Traditionally, prognostic models are developed from patient-specific infor-
mation including age, pathological subtype, molecular characterisation and
tumour staging, resulting in a clinical model, which characterises a patient’s
overall survival and the likelihood of the patient’s outcome. By combining the
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advanced quantitative analysis of medical imaging and clinically developed
prognostic models, it is hoped that the performance of prognostic models
can be improved. The advanced quantiative analysis of medical imaging
modalities is known as radiomics. Radiomic features aim to identify tumour
biomarkers and heterogeniety, through the extraction of high-dimensional
data, [15] that can be associated with metastatic growth, recurrence and
OS [92]. Radiomic features may also have significant prognostic value in the
management of cancer [93]. However, the extraction of radiomic features
and the results of radiomic analysis are dependent upon the method used to
delineate the MTV [17], with relatively few studies comparing the results of
radiomic analysis derived from each PET-AS method (cf. [94] and references
therein). Further, few studies have investigated the effect of radiomic analy-
sis from PET-AS methods on patient risk stratification [18,95,96]. Therefore,
this chapter aimed to evaluate the influence of PET-AS method MTV de-
lineation on patient risk stratification and the resulting patient OS, in OC,
by developing a series of prognostic models in the same patient cohort, with
identical clinical data and standardised radiomic features derived from dif-
ferent PET-AS methods. The following sections describe the materials &
methods used to achieve the aims of this chapter.
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3.1 Materials and methods
3.1.1 Patient Cohort
Four hundred and eighty six patients with biopsy-proven OC, including
Gastro-oesophageal junction (GOJ) tumours, were retrospectively identi-
fied for inclusion in this chapter. The identified patients were radiologi-
cally staged between 16th September 2010 and 31st July 2016 with stag-
ing performed according to the International Union Against Cancer (UICC)
TNM 7th edition [8] recommendations. The requirement for informed con-
sent from patients was waived by the Institutional Review Board after ap-
proval for patient inclusion in research studies (Wales REC 1, UK reference
14/WA/1208). Fourteen of the identified patients were initially excluded
due to having missing clinical data. Therefore, following the exclusions, 472
patients were selected for analysis and after contrast-enhanced CT staging
investigation, all of the included patients were deemed to have potentially
curable disease.
3.1.2 PET/CT protocol
Patients were fasted for at least 6 hours prior to 18F-FDG tracer administra-
tion and serum glucose levels were routinely checked and confirmed as less
than 7.0 mmol/L prior to PET/CT acquisition. Patients were injected with a
dose of 4 MBq of 18F-FDG/kg and rested for 90 minutes before scan acquisi-
tion, which is standard practice in our institution. PET/CT scan acquisition
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Figure 3.1: A GE 690 PET/CT scanner [97].
was performed using a GE 690 scanner (GE Healthcare, Buckinghamshire,
UK). The scanner is shown in Figure 3.1. CT images were acquired in a
helical acquisition with a pitch of 0.98 and tube rotation speed of 0.5 seconds
with a tube output of 120 kVp. Output modulation was between 20 and
200 mA. The matrix size for the CT acquisition was 512×512 pixels with
a 50 cm field of view with no oral or intravenous contrast administered to
patients before scanning. PET imaging was acquired at 3 minutes per field of
view using the VUE Point time of flight algorithm. The length of the axial
field of view was 15.7 cm (skull base to mid-thigh) and PET images were
reconstructed with the OSEM algorithm using 24 subsets and 2 iterations.
All PET based data was obtained using the same PET/CT scanner and re-
construction method with resulting voxel dimensions of 2.73×2.73×3.27 mm
and an axial slice matrix size of 256×256 voxels. A PET/CT scan demon-
strating FDG-avid uptake typical of the patient cohort is shown in Figure
3.2.
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Figure 3.2: A co-registered PET/CT scan from the patient cohort demon-
strating FDG-avid uptake.
3.1.3 Treatment Protocols
All patients began treatment 2-4 weeks after staging 18F-FDG PET/CT im-
age acquisition. Patients either had Endoscopic Mucosal Resection (EMR),
surgery alone, Neo-adjuvant chemotherapy (NACT) or Neo-adjuvant chemora-
diotherapy (NACRT) prior to surgery, Definitive chemoradiotherapy (dCRT)
or palliative therapy. The optimum treatment strategy was decided by con-
sensus at the MDT. In general, fit patients with tumours pre-operatively
staged as T3/T4a, N0/N1 were pre-operatively treated with NACT or NACRT.
Less fit patients, or those with T1/2 N0 disease, had surgery alone. TNM
staging is defined in Section 1.5. Whilst patients deemed unsuitable for
surgery due to co-morbidity and/or performance status, extensive loco-regional
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disease, or personal choice received dCRT.
3.1.4 Hardware and software
A 3.2 Ghz Intel Core i5 computer, with 16GB of RAM and a 2GB dedicated
AMD Radeon R9 M380 graphics processing unit (GPU) was used to process
PET/CT data in this project. PET-AS algorithms were implemented in the
Matlab programming language with a Matlab 2016b license (The Mathworks,
Natick, USA). Image processing and statistics toolbox licenses were installed
as well. Processing of the PET imaging for automated delineation of the
MTV was done with the open source software CERR [90].
3.1.5 Segmentation algorithms
The PET-AS methods included in this study were selected for having shown
promise for accurate MTV delineation [36]. The PET-AS methods are im-
plemented, as part of a common software package shown in Figure 3.3, as
fully automatic methods. In Figure 3.3, a ROI has been defined by the
user of the software in pink and the ATLAAS segmentation methodology
has been applied to the ROI. The resulting segmentation contour is shown
in black. Before definition of the ROI and segmentation with ATLAAS, a
reverse gray scale colour map was applied to PET image allowing for intu-
itive visualisation of the tumour. In a reverse gray scale colour map, areas of
higher metabolic uptake are shown as darker regions. In each case, the MTV
was defined using AT, Fuzzy C-means (FCM)2, GCM3, GCM4, KM2, KM3,
61
KM4, Region Growing (RG) and WT PET-AS methods. The parameters
and the number of clusters for each PET-AS method were chosen for use
in previous studies [77] and having demonstrated acceptable performance in
PET imaging [36]. The PET-AS methods were applied to a ROI that was
defined manually around the primary tumour by a clinical radiologist with
five years’ research experience. Contours derived by the nine PET-AS seg-
mentation methods were assessed by the same clinical radiologist subjectively
for accurate tumour representation. All tumour contours were visualised us-
ing the same software and image settings to ensure consistent methodology.
Segmentation methods were considered inadequate for further analysis if less
than 90% of contours were non-representative of the primary tumour. This
pre-defined value was decided upon prior to image visualisation. Contours
were assessed individually and classified as not representative if contours were
greatly different from the primary tumour, or included bone, lung or medis-
tinial tissue. In addition, segmentation methods that had failed or conformed
to the boundary of the bounding box were defined as not representative of the
primary tumour. Figure 3.4 demonstrates the different contours generated
by PET-AS methods and their considered acceptability. Five segmentation
methods denoted to have a poor MTV representation were excluded from
the study.
Adaptive Thresholding
AT is an iterative method, developed by Drever et al [66], that starts with
an initial fixed threshold method but it modifies the threshold value on each
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Figure 3.4: Metabolic tumour volume contours derived by PET automatic
segmentation methods for a patient that was excluded from the study due
to failed PET-based delineations. a) PET automatic segmentation method
contour conforming to the boundary region and rejected from the study b)
PET automatic segmentation method deriving multiple contours on a singu-
lar slice and rejected from the study c) PET automatic segmentation method
contour deemed to have acceptable metabolic tumour volume representation
and deemed acceptable for inclusion in this study
iteration of the algorithm until the change in volume between one iteration
and the next is less than two voxels. The equation for the initial threshold
is shown in Eq 3.1
T i = (initThresh× (SUV maxi − µ(backgroundi))) + µ(background)i (3.1)
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Where initThresh is the initial threshold value to be applied to the PET
image. In our implementation on iteration i = 1 the value is set at 0.45.
On subsequent iterations (i > 1) an initThresh of 0.4 is applied. SUV max
is the maximum SUV value within the region of interest on the PET im-
age for iteration i and µ(background) is the mean (µ) uptake defined as the
background within the PET image for iteration i. T i is the final absolute
threshold to apply to the PET image on the next iteration. The background
uptake of the PET image is initially defined as voxels within the PET image
with an intensity of < 50% of the SUVmax within the image. These parame-
ters were selected from a previous optimisation study performed by Berthon
et al [77].
Watershed Transform contouring
The implementation of this method is based upon the description in the
literature [70]. The algorithm uses Matlab’s Sobel filter for the definition of
the gradient map. WT finds the crests of the gradient map by simulating
water flooding from selected local minima in the gradient map. The flooding
of the gradient map continues until only one crest remains. This crest is
defined as the contour.
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Region Growing
RG is a procedure that groups voxels or subregions into larger regions based
on predefined criteria [98]. In this project the implementation of the RG
algorithm is based upon the method described by Day et al [68]. However,
the inclusion criteria, stopping criteria and initial voxels for consideration are
implemented differently. RG selects the SUVmax as its seed point and grows
a region from that voxel depending on the intensity of the voxel adjacent to
it. In our implementation an initial region is grown that considers voxels >
40% of the SUVmax. From this initial region, for each and every voxel the
neighbouring voxels are considered for inclusion as tumour. The criterion for
inclusion as tumour is based upon the µ tumour uptake and the SD from the
µ. In our implementation voxels are included if they are within twice the
SD of the µ. The µ tumour uptake is updated on each iteration. The region
stops growing once there is < 15% change in the tumour volume size from
one iteration to the next. These values were chosen due to good performance
in a number of phantom scans acquired at PETIC for the optimisation of
algorithms. Phantoms consisted of a variety of inserts with a µ volume
[range] of 15.27 [0.64 — 80.63] (mL) and µ tumour to background ratios
[range] of 10.49 [4.81 — 10.49].
Fuzzy Clustering
FCM was developed to account for the uncertainty arising at tumour bound-
aries in particular, by using a fuzzy classification instead of a binary one.
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It was based on the work described by Belhassen et al [71]. In this case,
each voxel is assigned a membership value for each cluster, ranging between
0 and 1. The membership value of a voxel x at iteration i is calculated as a
probability to belong to the cluster k considered, according to the difference
between the voxel intensity and the cluster µ intensity as shown in Eq 3.2.
Where uik is the probability of the voxel x belonging to cluster k on iteration
i, I(x) is the voxel intensity and M ik is the clusters µ intensity. A threshold is
applied to resulting probability map to generate the resulting contour. The
number of clusters used in this study is 2.
uik(x) =
||I(x)−M ik||∑
j ||I(x)−M ij ||
(3.2)
Gaussian Clustering
GCM is based on the FCM algorithm, with the difference that each cluster
is assumed to have a Gaussian intensity distribution, of which µ and SD are
calculated at each step. The cluster membership for each voxel is the prob-
ability of the voxel intensity value being generated by the cluster Gaussian
distribution as shown in Eq 3.3. Where (σik)
2 is the variance of the intensi-
ties in cluster k at iteration i. The method is implemented based upon the
description by Hatt et al [72]. The number of clusters used in this study are
3 and 4.
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uik(x) = exp
(
− ||I(x)−M
i
k||2
2(σik)
2
)
(3.3)
K-means clustering
KM assigns each voxel of the initial image to the cluster with a µ intensity
value closest to its own value. This is algorithms implementation is based on
the description by Zaidi et al [35]. However, it uses a customised initialisation
criterion, considering a partition of the image intensity range into the number
K of levels chosen by the user. The number clusters used in this study are
2, 3 and 4.
3.1.6 Clinical Data & image analysis
Only primary tumours were analysed to ensure consistent methodology across
all patients. Before quantitative image analysis and texture feature extrac-
tion, PET images were re-sampled into fixed bin widths of 0.5 SUVs. A
fixed bin width maintains a constant intensity resolution when compared
to approaches based on a fixed number of bins [99]. In the development
of the prognostic models, age at diagnosis (number of years), radiological
stage (stage IA—IV) and treatment (curative vs palliative) were included
because these are strong predictors of survival [100]. Curative and palliative
treatments were coded as 1 and 2 respectively. Radiological staging for the
purposes of prognostic model development was represented categorically. A
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patient with Stage IIA cancer was passed to the step-wise cox proportional
hazards method as “Stage IIA”, the statistics package then automatically
converts the patient’s staging into a numerical value. For example, “Stage
IIA” is converted to 2.25 and Stage IIB is converted to 2.75. In cox propor-
tional hazard methods, a reported variables hazard ratio is the proportion of
how likely an event (death in this body of work) occurs in comparison to the
proportion when all reported variables are zero. Therefore, a hazard ratio
>1 in this body of work indicates a decrease in OS, whereas a hazard ratio
<1 indicates an increase in OS.
Analysis of radiomic features (See Section 1.5) was performed using algo-
rithms implemented as part of the Image Biomarker Standardisation Initia-
tive (IBSI), a multicentre, international collaboration aimed at improving the
reproducibility and validation of quantitative medical image analysis stud-
ies [15]. The radiomic features selected for inclusion in this study were chosen
as they have shown prognostic and predictive significance in other radiomic
studies investigating OC [95, 101, 102]. These have been summarised in Ta-
ble 3.1. Moreover, many radiomic feature implementations have been de-
scribed [92,93,101,103]. For radiomic feature extraction in this chapter, the
MTV was analysed as a three dimensional (3D) volume with no thresholding
applied to the MTV mask.
First Order radiomic features
First order statistical metrics summarise the voxel intensity distribution
within the segmented MTV, without concern for spatial relationships [104].
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First order metrics are typically histogram based and reduce the MTV to
singular values describing the µ, minimum, maximum, median, uniformity
of the intensities within the MTV. Included in first order stastical analysis
is Skewness (asymmetry measure), Kurtosis (pointiness measure) and En-
tropy (randomness measure). Kurtosis and skewness have been shown to be
independent predictors of survival [16], and of prognostic significance in the
literature [105].
Higher Order radiomic features
Higher order statistical metrics retain spatial information and are used to
quantify inter-voxel intensity relationships. Dissimilarity is the quantification
of variation in voxel pairs and is calculated using a Grey Level Co-occurrence
Matrix (GLCM) generated for each unique direction and averaged. A low
dissimilarity is a result of neighboring voxels having similar values [106]. Zone
percentage is calculated from a Grey Level Size Zone matrix (GLSZM) by
assessing the fraction of recorded zones compared to the maximum number
of possible zones. Heterogeneous MTVs have high zone percentage scores.
Grey Level Non-Uniformity (GLNU) is an evaluation of the distribution of
zone counts for each intensity value. The feature value is low when the num-
ber of zones associated with each intensity value are similar. Coarseness is
a Neighborhood Grey-Tone Difference Matrix (NGTDM) feature that gives
an indication of the level of spatial rate of change in intensity [107]. GLCM,
GLSZM, NGTDM can be computed in 2D or 3D. The matrices in this study
were computed in 3D as this may highlight the multi-scale, directional prop-
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erties of tumour tissue [108].
Patient’s outcome and overall survival data
The primary outcome in this patient cohort was OS, defined as number of
months survived from date of diagnosis. Patients were followed-up 3-monthly
for the first year, 6-monthly until 5 years then annually thereafter, or until
death. All of the included patients were followed-up for at least 12 months.
A patient’s date of death obtained from the Cancer Network Information
System Cymru database (CaNISC, Velindre NHS Trust, Wales).
Statistical Analysis
Categorical variables were described as frequency (percent) and continuous
variables as median (range) and differences assessed with appropriate non-
parametric tests. Cumulative survival was calculated by the Kaplan-Meier
life-table method. Cox regression models with backward conditional method
were constructed using identical clinical data and imaging data derived from
each of the segmentation methods. An individual prognostic score was calcu-
lated from each segmentation method by summation of the products of vari-
ables and their corresponding parameter estimate. Using this score, patients
were separated into low, intermediate and high-risk groups (higher prog-
nostic score deemed higher risk) and a log-rank test evaluated significant
differences in OS. The number of patients that changed risk stratification
group depending on the segmentation method used was calculated, and the
OS for the different risk groups between models was analysed. The Akaike
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information criterion (AIC) statistic evaluated the estimated quality of the
models [109]. Given a set of developed models, AIC estimates the quality of a
developed model from other developed models by estimating the information
lost by the model being assessed. The model with the lowest AIC value and
therefore the lowest information loss, is considered the better model. AIC
was chosen for the comparison of developed models, instead of the Bayesian
information criterion (BIC), due to being being designed to select predic-
tive models, whereas BIC is designed to find the true (known) model that
represents the data. A p-value of <0.05 was considered statistically signifi-
cant. Statistical analysis was performed using SAS version 9.4 (SAS, North
Carolina, USA) and SPSS version 23.0 (IBM, Chicago, USA).
3.2 Results
The study in this chapter involved four hundred and seventy-two patients,
each with 9 MTV contours delineated by AT, FCM2, GCM3, GCM4, KM2,
KM3, KM4, RG and WT PET-AS methods. The contours were assessed by
a clinical radiologist for accurate tumour representation; after which, forty-
five patients and 5 segmentation methods were excluded due to poor MTV
delineation. FCM2 failed to delineate an acceptable tumour representation in
145 (30.8%) of cases. KM3 and KM4 failed in 88 (18.6%) and 215 (45.6%) of
cases, respectively. RG failed in 389 (82.5%), and GCM4 in 33 (7%) of cases.
Therefore, 427 cases with MTVs delineated with KM2, GCM3, AT and WT
PET-AS methods were deemed to have accurate tumour representation and
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included for further analysis. The 427 cases included for analysis were used
to develop the prognostic models for KM2, WT, GCM3 and AT methods.
Baseline characteristics of patients are detailed in Table 3.2. The median
OS of the cohort was 17.0 months (95% confidence interval (95% CI) 14.8
— 19.2). Median follow-up was 35.0 months (95% CI 28.7 — 41.3). Overall
1— and 2— year survival in the development cohort was 65.3% and 30.1%,
respectively.
3.2.1 Development of Prognostic Models
The final steps of each prognostic model are presented in Table 3.3. Three
known clinical prognostic factors (age, radiological stage and treatment) re-
mained in each derived model, but there was a difference in the inclusion of
texture metrics by segmentation technique. AT and KM2 produced the same
model output. In comparison to a study published by Foley et al [16], in this
chapter radiomic features were not included in the final models for these seg-
mentation methods. However, in this body of work radiomic features were
implemented according to IBSI specifications. Additionally, the radiomic fea-
tures skewness and kurtosis were found to be independently significant for
survival using the GCM3 method. Skewness and GLNU were significant us-
ing the WT method. Their inclusion in the models illustrates their additional
prognostic value compared with current prognostic factors.
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3.2.2 Prognostic Score Calculation
The equations for each model, derived from different segmentation methods,
were used to calculate the prognostic scores, and are listed in Table 3.4.
These calculations were derived using published methods [110].
Figure 3.5 shows the risk stratification (see Section 1.5) for WT, KM2, AT,
and GCM3. In Figure 3.5, for the AT and KM2 derived prognostic models,
the median OS for the low risk, intermediate risk and high-risk groups was
36.0 months (29.9 — 42.1 months), 18.0 months (15.1 — 20.9 months) and
9.0 months (7.8 — 10.2 months) respectively. In comparison, the median OS
for the low risk, intermediate risk and high-risk group in the GCM3 derived
prognostic model was 36.0 months (28.8 — 43.2 months), 18.0 months (15.4
— 20.6 months) and 9.0 months (7.7 — 19.2 months). Additionally, in Figure
3.5, the median OS for the WT derived prognostic model low risk, interme-
diate and high-risk groups was 36 months (27.8 — 44.2 months), 19 months
(15.1 — 23 months) and 9 months (7.7 — 10.3 months) respectively.
Table 3.5 shows the number of patients stratified as low, intermediate and
high risk for each single prognostic model along with the prognostic score
range for each risk stratification group. There was no significant difference
in the number of patients stratified as low risk between the prognostic models
(P = 1). Additionally, no significant difference was found between the num-
ber of patients stratified as intermediate risk or high risk (P = 1). Therefore,
each of the developed prognostic models stratified the patients equally. How-
ever, Table 3.6 shows the number of patients who change risk stratification
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when risk stratified from the prognostic models. The largest proportion of
patients to change risk stratification group was between prognostic models
based on GCM3 and on WT (n=73, 17.1%). Patients that change risk strati-
fication have the potential to receive different treatments. However, it can be
noted that no patient changed risk stratification group between AT and KM2
because the prognostic models were identical. Whilst patients were found to
change risk stratification, there was no overall survival difference between
AT, GCM3, KM2 or WT low-risk groups (χ2 = 0.052, df = 3, p = 0.997),
intermediate-risk groups (χ2 = 0.016, df = 3, p = 0.999) or high-risk groups
(χ2 = 0.028, df = 3, p = 0.999). To estimate the quality and performance of
the developed prognostic model, the AIC statistic was calculated, for which
the lowest score assumes a higher quality model due to less information loss.
The AIC statistics for GCM3, WT and AT/KM2 was 3044, 3048 and 3052
respectively. Therefore, the AIC statistic suggests that GCM3 has the best
estimated model performance.
Prognostic models were also developed using the segmentation methods FCM2,
GCM4, KM3, KM4 and RG. These segmentation methods were excluded
from the main study because the assessing radiologist deemed the contours
to not be representative in less than 90% of cases. However, the models are
included here for completeness. The final steps of each prognostic model are
presented in Table 3.7. Whilst the contours produced using AT and KM2
were considered by the radiologist to be acceptable, the contours produced
by the FCM2, KM4 and RG PET-AS methods were considered to be not
acceptable. However, the final steps in these prognostic models only used
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the clinical variables age, treatment and stage. Additionally, the parameter
estimate and hazard ratio for each of the clinical variables was the same.
This is demonstrated in Table 3.8, where the equations for each excluded
model are presented.
Table 3.9 outlines the summary statistics of median OS (95% CI) for GCM4,
FCM2, KM3, KM4 and RG PET-AS methods and Figure 3.6 shows the OS
for prognostic models developed from PET-AS methods excluded from the
study. The median OS for the low risk, intermediate and high risk groups for
the models developed from the excluded PET-AS methods was 36, 18 and 9
months respectively. In addition, Table 3.10 shows the number of patients
in each risk stratification group for each of the developed models. There
was no significant difference in the number of patients between each risk
stratification group (P = 1). Additionally for the excluded PET-AS methods,
in comparison to the acceptable PET-AS methods, there was no significant
difference in the number of patients in each risk stratification group (P = 1).
Table 3.11 shows the total number of patients and percentage that change
risk-stratification group between each prognostic model.
3.3 Discussion
The aim of this chapter was to highlight the need for a standardised MTV
delineation method in the development of prognostic models as well as to
investigate the impact of MTV delineation on patient risk stratification and
therefore a patient’s OS. In order to achieve this, first, second and higher-
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order radiomic features were extracted from 9 differing PET-AS delineations.
The results presented in this chapter demonstrate that the significant vari-
ables in the developed prognostic models are dependent upon the MTV de-
lineation method. For example, in the prognostic model developed from
the PET-AS method GCM3, the first-order radiomic features Kurtosis and
Skewness were found to be significant predictors of a patient’s OS. In com-
parison, in the prognostic model developed from the WT PET-AS method,
the higher-order feature GLNU was found to be of significance, as well as
Skewness. Whilst radiomic features were significant in the development of
the GCM3 and WT based prognostic models, in the AT and KM2 PET-AS
method based prognostic models, radiomic features were found not to be sig-
nificant predictors of a patient’s OS. This is in addition to the known clinical
predictors, which include a patient’s TNM staging and age. Therefore, the
results presented in this chapter highlight the dependency of significant PET
radiomic variables on the MTV delineation method.
For each unique prognostic model, patients were also found to change risk
stratification group and the AIC statistic for each model suggested that the
PET-AS method GCM3 has the best prognostic performance, in compari-
son to the WT and AT/KM2 developed models. The small difference in the
AIC statistic between the developed prognostic models, suggests that there
is a relatively small difference in the effect of the different PET-AS meth-
ods on patient risk stratification between each of the developed prognostic
models.
Nine PET-AS delineation methods were used to derive MTVs in this chapter
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and the delineated contours were reviewed by a radiologist. After assessment,
5 of the PET-AS methods were excluded from analysis due to due to poor
tumour representation in the majority of cases. However, upon investigation
the prognostic models developed by the excluded PET-AS methods (FCM2,
KM3, KM4 and RG) developed identical prognostic models to the PET-AS
methods AT and KM2. Therefore, whilst radiomic features which are consid-
ered significant and associated with a patient’s OS are dependent upon the
delineation method, this is potentially unrelated to the PET-AS method con-
tours considered acceptable by a radiologist. The presented results demon-
strate that patients are potentially assigned to different risk stratification
groups depending on the MTV delineation method. This is could be signifi-
cant as sub-groups of patients have the potential to receive more aggressive
treatments than is necessary. Therefore, patients have the potential to have
a decreased quality of life. In reverse, this has the potential for patients to
be denied beneficial treatment.
Morphological features, which describe a tumour’s shape, can also be quan-
tified from the MTV. Within this group of radiomic features, the surface
to volume ratio, compactness, sphericity and disproportion of the tumour
can be characterised. Morphological features were not included in this chap-
ter because the experiment focused upon radiomic features which are po-
tential biomarkers for intra-tumoural heterogeneity. However, studies have
investigated the inclusion of shape metrics in prognostic models [111]. The
variability in PET-AS performance in any one single clinical case means the
standardisation of the delineation of the MTV is critical for the application of
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radiomics within OC, especially as the findings in this chapter demonstrate
the potential impact of different MTV delineation methods on the develop-
ment of prognostic models, even when using standardised implementations
of radiomic features.
This supports the recommendations of the IAEA [31] and the AAPM Task
Group No 211 [1] as they independently reported that they could not recom-
mend a single PET-AS method for MTV delineation. Therefore, an agreed
upon PET-AS method should be used for MTV delineation when developing
and using prognostic models.
3.4 Conclusion
Prognostic models incorporating quantitative image features are dependent
on the method used to delineate the primary tumour. This has a subsequent
effect on risk stratification, with patients changing groups depending on the
PET-AS method used to delineate the MTV. The findings of this study may
have substantial potential impact on clinical management of patients with
OC and were published in EJNMMI Res (2018) [38]. This work has shown
that the standardisation of PET segmentation is important and should be
considered in future prognostic and predictive clinical models. The following
chapter aims to externally validate the ATLAAS segmentation methodology,
which has been proposed for the standardised delineation of the MTV for
RT planning [36].
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Table 3.1: Summary of quantitative imaging features
Type / Order of
statistics
Feature Brief Definition
Morphological Volume Sum of voxels delineated
multiplied by the volume of
one voxel
Pre-
discretisation
SUVmax Maximum uptake of FDG in
the MTV
Energy Sum squared SUV values in
the MTV
First order Skewness Measures symmetry of in-
tensity histogram
Kurtosis Measures flatness of inten-
sity histogram
Entropy Measures randomness
Second order Dissimilarity Variation of grey level pairs
(GLCM). Features were cal-
culated for each unique di-
rection and averaged with a
distance setting of 1.
Higher order Grey-level Non-uniformity Distribution of zone counts
for each intensity value
(GLSZM)
Zone Percentage Fraction of recorded zones
compared to maximum pos-
sible
Coarseness Measures spatial rate of
change in intensity using a
distance of 1.
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Table 3.2: Baseline characteristics of patient cohort
Median age 67.0 year (range 24 — 84)
Gender Male 315 (73.8% of included patients): Female 112
(26.2% of included patients)
Histology number of patients (% of total number patients)
Adenocarcinoma 313 (73.3%)
Squamous Cell Carcinoma 100 (23.4%)
Undifferentiated 5 (1.2%)
High-grade Dysplasia 4 (0.9%)
Neuro-endocrine 3 (0.7%)
Small Cell Carcinoma 1 (0.2%)
Sarcoma 1 (0.2%)
Tumour Location number of patients (% of total number patients)
Oesophagus 268 (62.8%)
Upper third 14 (5.2%)
Middle third 71 (26.5%)
Lower Third 183 (68.3%)
Gastro-oesophageal junction 159 (37.2%)
Siewert I 67 (42.1%)
Siewert II 42 (26.4%)
Siewert III 50 (31.4%)
Stage Group number of patients (% of total number patients)
IA 10 (2.3%)
IB 17 (4.0%)
IIA 70 (16.4%)
IIB 13 (3.0%)
IIIA 97 (22.7%)
IIIB 52 (12.2%)
IIIC 76 (17.8%)
IV 92 (21.5%)
Treatment number of patients (% of total number patients)
Curative 224 (52.5%)
NACT 86 (38.4%)
dCRT 86 (38.4%)
Surgery Alone 31 (13.8%)
NACRT 20 (8.9%)
EMR 1 (0.5%)
Palliative 203 (47.5%)
Mortality number of patients (% of total number patients)
Alive 132 (30.9%)
Dead 295 (69.1%)
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Table 3.3: Final Output of Prognostic Models Derived Using AT, GCM3,
KM2 and WT PET Segmentation Methods
AT Parameter Estimate p-value Hazard Ratio 95% CI
Age 0.020 0.001 1.020 1.008 — 1.033
Treatment -1.075 <0.001 0.341 0.254 — 0.459
Stage 0.144 <0.001 1.155 1.072 — 1.245
GCM3 Parameter Estimate p-value Hazard Ratio 95% CI
Age 0.019 0.003 1.019 1.006 — 1.032
Treatment -1.024 <0.001 0.359 0.266 — 0.485
Stage 0.142 <0.001 1.153 1.068 — 1.245
Kurtosis 0.632 0.002 1.882 1.260 — 2.809
Skewness -0.789 0.044 0.454 0.211 — 0.980
KM2 Parameter Estimate p-value Hazard Ratio 95% CI
Age 0.020 0.001 1.020 1.008 — 1.033
Treatment -1.075 <0.001 0.341 0.254 — 0.459
Stage 0.144 <0.001 1.155 1.072 — 1.245
WT Parameter Estimate p-value Hazard Ratio 95% CI
Age 0.018 0.004 1.018 1.006 — 1.031
Treatment -1.063 <0.001 0.345 0.257 — 0.464
Stage 0.140 <0.001 1.150 1.065 — 1.242
GLNU 0.017 0.006 1.017 1.005 — 1.029
Skewness 0.674 0.030 1.962 1.067 — 3.607
Table 3.4: Prognostic model equations
Segmentation
Method
Prognostic Model Equation
AT (Age× 0.020)− (Treatment× 1.075) + (Stage× 0.144)
GCM3 (Age×0.019)−(Treatment×1.024)+(Stage×0.142)−
(Skewness× 0.789) + (Kurtosis× 0.632)
KM2 (Age× 0.020)− (Treatment× 1.075) + (Stage× 0.144)
WT (Age×0.018)−(Treatment×1.063)+(Stage×0.140)+
(Skewness× 0.674) + (GLNU × 0.017)
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(a) AT (b) GCM3
(c) KM2 (d) WT
Figure 3.5: Patient risk stratification for AT, KM2, GCM3 and WT PET-AS
methods. The median overall survival for the low risk groups in the models
developed from AT, GCM3, KM2 and WT was 36 months. The median
overall survival for the intermediate risk groups in the models developed
from AT, GCM3 and KM2 was 18 months. However, the median overall
survival for WT intermediate risk group was 19 months. The median overall
survival for the high risk groups in the models developed from AT, GCM3,
KM2 and WT was 9 months.
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(a) GCM4 (b) FCM2, KM3, KM4 and RG
Figure 3.6: Patient risk stratification for excluded PET-AS methods. The
median overall survival for the low risk group in the GCM4 derived model
was 36 months (27.4 — 44.6) and 36 months (29.9 — 42.1) in the models
derived by FCM2, KM3, KM4 and RG. The median overall survival for the
intermediate risk group in the GCM4 derived model was 18 months (14.6 —
21.4) and 18 months (15.1 — 20.9) in the models derived by FCM2, KM3,
KM4 and RG. The median overall survival for the high risk group in the
GCM4 derived model was 9 months (7.7 — 10.3) and 9 months (7.8 — 10.2)
in the models derived by FCM2, KM3, KM4 and RG.
Table 3.5: Number of patients in each risk stratification group for each single
prognostic model, with the prognostic score range given in brackets
number in risk
group
Low Risk
(prognostic
score range)
Intermediate Risk High Risk
AT\KM2 141 (-0.45 —
0.98)
143 (0.99 — 2.16) 143 (2.17 — 2.79)
GCM3 140 (-1.13 —
0.36)
143 (0.37 — 1.54) 144 (1.55 — 2.73)
WT 142 (-0.17 —
1.30)
144 (1.31 — 2.48) 141 (2.49 — 3.62)
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Table 3.6: Total number of patients and percentage that change risk-
stratification group
Number changing group (%) AT GCM3 KM2 WT
AT
GCM3 66 (15.4)
KM2 0 (0.0) 66 (15.4)
WT 57 (13.3) 73 (17.1) 57 (13.3)
Table 3.7: Final Output of Prognostic Models Derived Using FCM2, GCM4,
KM3, KM4 and RG PET-AS methods
FCM2 Parameter Estimate p-value Hazard Ratio 95% CI
Age 0.020 0.001 1.020 1.008 — 1.033
Treatment -1.075 <0.001 0.341 0.254 — 0.459
Stage 0.144 <0.001 1.155 1.072 — 1.245
GCM4 Parameter Estimate p-value Hazard Ratio 95% CI
Age 0.020 0.001 1.021 1.008 — 1.033
Treatment -1.055 <0.001 0.348 0.259 — 0.469
Stage 0.159 <0.001 1.172 1.086 — 1.265
Kurtosis 0.207 0.016 1.230 1.039 — 1.455
KM3 Parameter Estimate p-value Hazard Ratio 95% CI
Age 0.020 0.001 1.020 1.008 — 1.033
Treatment -1.075 <0.001 0.341 0.254 — 0.459
Stage 0.144 <0.001 1.155 1.072 — 1.245
KM4 Parameter Estimate p-value Hazard Ratio 95% CI
Age 0.020 0.001 1.020 1.008 — 1.033
Treatment -1.075 <0.001 0.341 0.254 — 0.459
Stage 0.144 <0.001 1.155 1.072 — 1.245
RG Parameter Estimate p-value Hazard Ratio 95% CI
Age 0.020 0.001 1.020 1.008 — 1.033
Treatment -1.075 <0.001 0.341 0.254 — 0.459
Stage 0.144 <0.001 1.155 1.072 — 1.245
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Table 3.8: Prognostic model equations developed from excluded PET-AS
methods
Segmentation
Method
Prognostic Model Equation
FCM2 (Age× 0.020)− (Treatment× 1.075) + (Stage× 0.144)
GCM4 (Age×0.020)−(Treatment×1.055)+(Stage×0.159)+
(Kurtosis× 0.207)
KM3 (Age× 0.020)− (Treatment× 1.075) + (Stage× 0.144)
KM4 (Age× 0.020)− (Treatment× 1.075) + (Stage× 0.144)
RG (Age× 0.020)− (Treatment× 1.075) + (Stage× 0.144)
Table 3.9: Summary statistics of median OS (95% CI) for GCM4, FCM2,
KM3, KM4 and RG
95% Confidence Intervals
Segmentation Method Risk Group Median OS Lower Upper
GCM4 Low 36.0 27.4 44.6
Intermediate 18.0 14.6 21.4
High 9.0 7.7 10.3
FCM2, KM3, KM4, RG Low 36.0 29.9 42.1
Intermediate 18.0 15.1 20.9
High 9.0 7.8 10.2
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Table 3.10: Number of patients in each risk stratification group, with the
prognostic range in brackets, for GCM4, FCM2, KM3 and RG developed
prognostic models
number in risk
group
Low Risk
(prognostic
range)
Intermediate Risk High Risk
FCM2\KM3\
KM4\RG
141 (-0.45 —
0.98)
143 (0.99 — 2.16) 143 (2.17 — 2.79)
GCM4 141 (-0.13 —
1.02)
142 (1.03 — 2.19) 144 (2.20 — 3.14)
Table 3.11: Total number of patients and percentage that change risk-
stratification group for excluded PET-AS methods
Number
changing
group (%)
AT\FCM2
KM2\KM3
KM4\RG
GCM3 GCM4 WT
GCM3 66 (15.4)
GCM4 51 (11.9) 65 (15.2)
WT 57 (13.3) 73 (17.1) 68 (15.9)
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Chapter 4
Automated segmentation of the
metabolic tumour volume in
low tumour to background
ratio PET
H&N cancer is the sixth most common tumour worldwide [3], with rates of
incidence in the UK increasing by 30% since the early 1990s [5]. RT is often
used to treat Oropharyngeal (OP) SCC and 18F-FDG PET aids MTV delin-
eation in RT planning. Typically, RT planning is performed on CT imaging
acquired before RT; however there is increasing interest in multi-modality
treatment pathways, as induction chemotherapy (ICT) before RT can lead
to tumour downstaging and a reduced MTV [112]. Therefore, RT planning
and MTV delineation on pre-ICT PET imaging potentially means the de-
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lineated tumour shape, size and volume may be misrepresented when RT
treatment starts, leading to inaccuracies in RT planning, which can result in
an increased dose to the OAR. Further, MTV delineation on PET imaging
acquired after ICT is challenging due to the reduced metabolic activity and
MTV. The aim of the study, presented in this chapter therefore, was to eval-
uate PET-AS methods including the machine-learned method ATLAAS for
MTV delineation on PET imaging after ICT. The following section describes
the materials & methods used to achieve this aim.
4.1 Materials and Methods
4.1.1 Clinical Data
The patients analysed in this chapter were identified from a phase I, multi-
centre, feasibility trial called 18F-FDG-PET Guided Dose-Painting With In-
tensity Modulated Radiotherapy in Oropharyngeal Tumours (FiGaRO) [113]
conducted in the following centres:
• Guy’s and St Thomas’ Hospitals (London,UK)
• Velindre Cancer Centre (Cardiff, UK)
It investigated dose escalation of residual metabolic uptake on 18F-FDG PET
imaging acquired following 1 cycle of ICT, in patients with primary OP SCC,
with the aim of improving tumour control rates whilst delivering acceptable
toxicity levels. ICT within the trial consisted of a combination of Cisplatin
and 5-Fluorouracil (5FU) and ethical approval for the trial, by the research
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ethics committee, was granted in July 2012 (REC: 12/LO/1724). All patients
provided written informed consent for inclusion in the trial and for research
purposes.
Twenty-three patients were enrolled on the trial between October 2013 and
March 2017 and were excluded from the trial if they had previously received
RT treatment to the H&N region, had a previous malignancy except for
non-melanoma skin cancer or had previous/concurrent illness. In total, three
patients were excluded from the trial. One patient was excluded from the trial
because, after delivery of one cycle of ICT, the residual MTV was considered
too small for effective dose escalation. A further two patients were also
excluded from the study due to technical and unrelated medical problems.
Therefore, twenty patients proceeded to have dose-escalated IMRT. Analysis
of the MTVs delineated for planning IMRT showed one PET scan had two
disjointed MTVs. Therefore, twenty-one separate MTVs were available for
analysis in this chapter.
Patients recruited to the trial had histologically confirmed OP SCC, assessed
as either HPV negative by p16 immunohistochemistry and in-situ hybridiza-
tion for high-risk subtype DNA, or intermediate or high risk HPV positive.
Patients were also defined as having a greater than 10 pack/year smoking
history, were over 18 years old, staged with at least T2 tumours and had
advanced N stage (TNM v7 N2b, N2c, N3) [9]. TNM staging is defined in
Section 1.5. All patients were planned for treatment with 2 cycles of ICT
followed by primary radical IMRT to the primary and bilateral neck nodes.
Radical IMRT occurred concurrently with Cisplatin chemotherapy (chemo-
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IMRT). The pathway for patients recruited to the FiGaRO trial is shown in
Figure 4.1. Patients were referred from Oncology before consenting to the
study and then undergoing the 1st cycle of ICT. Three weeks after the 1st
cycle of ICT, PET/CT imaging was acquired for RT planning. The following
section describes the PET/CT imaging protocol for each patient.
4.1.2 18F-FDG PET/CT imaging
For planning IMRT, 18F-FDG PET/CT imaging was acquired in the treat-
ment position using a H&N immobilisation shell. Figure 4.2 shows a typical
RT immobilisation shell applied to a dummy patient. The shells are typi-
cally made using a mesh structure with lots of small holes and are designed
to keep the area that they are applied to completely still. RT masks also
ensure repeated (fractionated) RT deliveries are delivered to the same region
each time. This is because the RT mask can be marked and then aligned
with lasers on the linacs. In addition to acquisition of the planning 18F-FDG
PET imaging, a contrast enhanced CT scan and a low dose CT scan were
acquired. Figure 4.3 shows an example of a low dose CT scan and contrast
enhanced CT scan. A patient who has a low dose CT scan receives a lower
radiation dose compared to a normal CT scan. Therefore, a low dose CT
scan is typically used for the diagnosis of cancer as patients can receive mul-
tiple scans for the same level of radiation exposure as a normal dose CT scan.
The low dose CT scan was used for attenuation correction of PET imaging
only. All imaging acquired for planning IMRT purposes was acquired 3 weeks
following the first cycle of ICT.
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Completion of chemoradiotherapy
Start of chemoradiotherapy
6 weeks of radiotherapy daily 
Monday - Friday
HNC MDT/Oncology Referral
1st Oncology Appointment
Radiotherapy shell made
Radiotherapy planning
3 dose plan in 30 fractions
65 Gy to PTV
71.5 Gy to MTV
Patient recruited & 
consents to study
Planning PET/CT (in radiotherapy 
position)
1st Cycle of 5FU induction 
chemotherapy
MTV manually delineated
ATLAAS MTV outlined
2nd Cycle of 5FU induction 
chemotherapy
Figure 4.1: Pathway for patients recruited to the FiGaRo trial
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Figure 4.2: RT immobilisation shells are used during RT treatment in order to
minimise movement from a patient and therefore ensure RT is delivered with
a high-degree of accuracy. Immobilisation shells are typically made using a
mesh structure. Image reproduced courtesy of Cancer Research UK [114].
(a) Low dose CT scan (b) Contrast enhanced CT scan
Figure 4.3: (a) Low dose CT scan acquired for attenuation correction of PET
imaging used for radiotherapy planning in the FiGaRo trial. (b) Contrast
enhanced CT scan acquired after acquisition of PET imaging. Low dose CT
scans are acquired with a lower x-ray tube current causing patients to receive
a lower radiation dose. Therefore, they are typically used diagnostically as
patients can undertake multiple scans for the same level of radiation exposure
as a normal dose CT scan.
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Figure 4.4: A GE 710 PET/CT scanner [115].
Before PET/CT scanning with either a GE Discovery 710 situated in London
or a GE Discovery 690 situated in Cardiff, patients were injected with 350+/-
10% MBq of 18F-FDG and rested for 90 minutes. Figure 3.1 in Chapter 3
shows a GE 690 PET scanner and Figure 4.4 shows a GE 710 PET scanner.
All of the PET images were acquired with a field of view of 700 mm and a
matrix size of 256×256 voxels. The resulting PET image voxel dimensions
were 2.73×2.73 mm with a slice thickness of 3.27 mm. Further, all of the
PET images were acquired using a total of 3 bed positions at 4 minutes per
bed position and TOF data, which was used during PET reconstruction. The
acquired PET data was reconstructed using OSEM, with 2 iterations and 24
subsets, and a 6.4 mm Full Width at Half Maximum (FWHM) Gaussian post
filter was applied to the images after reconstruction. RT planning requires
the delineation of the target tumour volume, in the form of the MTV on PET
imaging. For the patients included in the FiGaRO trial, the primary MTV
for IMRT planning was delineated manually on the PET imaging acquired
after one cycle of ICT, according to the process described in the following
section.
94
4.1.3 Manual MTV delineation after 1 cycle of chemother-
apy
Manual MTV PET delineation in this study was performed by a nuclear
medicine physician and a clinical oncologist jointly, with differences in delin-
eation resolved by consensus; multi-disciplinary approaches have been shown
to reduce intra and inter-observer variability [116]. Additionally, it is cur-
rently recommended to use fixed windowing and viewing levels, when delin-
eating the MTV [117,118], in order to further reduce intra and inter-observer
variability. Therefore, PET images were displayed in SUV and visualised us-
ing an inverse linear colour scale with a fixed windowing level and width.
All PET data was scaled to a SUV range of 0 to 10. The manually delin-
eated PET MTV was used for RT planning and as the reference MTV within
this chapter. MTV delineation was performed using Hermes Hybrid Viewer
(Hermes Medical Solutions, Sweden) versions 2.2C and 2.6H at Guys & St
Thomas PET Centre and Velocity AI version 2.7 (Varian Medical Systems,
Palo Alto, USA) and ProSoma version 3.2 (OSL Oncology Systems Limited,
UK) at Velindre Cancer Centre.
4.1.4 Development of ATLAASICT
ATLAAS has been described in detail in Chapter 2 Section 2.4 [65]. The
statistical model for ATLAAS was originally developed on pre-treatment
H&N 18F-FDG PET imaging data using the following image and tumour
parameters: TBR, MTV and NI. In this chapter, this training dataset is
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known as ATLAASORIG and therefore, as manual delineation of the MTV
and IMRT planning was performed using PET imaging acquired after one
cycle of ICT, we compared the characteristics of the PET imaging and MTVs
obtained on pre-ICT and post-ICT PET imaging, in order to understand the
effect of one cycle of ICT on primary tumour volumes.
Comparison of pre-ICT and post-ICT PET imaging
To standardise the comparison of MTVs on pre- and post-ICT PET imaging,
contours were delineated using 42% SUVpeak thresholding. Figure 4.5a and
Figure 4.5b compares the MTV contours derived by 42% SUVpeak thresh-
olding on PET images acquired for diagnosis and RT planning purposes.
The 42% SUVpeak MTV on PET imaging acquired for diagnostic purposes
in Figure 4.5a had a SUVmax of 6.69 and SUVpeak of 5.03 with a volume of
8.76 mL. In comparison, the 42% SUVpeak derived MTV on PET imaging
acquired for RT planning in Figure 4.5b had a SUVmax of 7.11 and SUVpeak
of 5.09 with a volume of 10.01 mL. The increased MTV derived on Figure
4.5b is due to the decreased metabolic activity of the MTV, as the appro-
priate threshold to delineate the MTV is dependent upon the SUVmax and
SUVpeak [32]. However, Table 4.1 shows that ICT reduced the MTV, SUVmax,
TBR and NI values when contoured using 42% SUVpeak thresholding. The
results presented demonstrate that there were significant differences in the
characteristics of pre-ICT PET imaging, which ATLAAS was trained upon,
and the characteristics of post-ICT PET imaging; therefore, simulation and
development of new PET scans with characteristics of post-ICT PET scans
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(a) 42 % SUV peak thresholding on
pre-ICT PET imaging
(b) 42 % SUV peak thresholding on
post-ICT PET imaging
Figure 4.5: Pre and Post-ICT PET imaging
was required for accurate MTV delineation.
Table 4.1: Mean [Range] MTV, TBR, SUVMAX and NI on
18F-FDG PET
imaging acquired before and after ICT when contoured using 42% SUVPEAK
fixed thresholding
Parameter Before ICT
18F-FDG PET
After ICT
18F-FDG PET
Mean MTV (mL) 9.67 [2.79 — 36.18] 7.43 [3.81 — 15.11]
Mean TBR 2.16 [1.77 — 2.69] 1.79 [1.32 — 2.31]
Mean SUVmax 16.05
[6.96 — 32.96]
10.93 [4.73 — 25.00]
Mean NI 59.75 [45.00 — 65.00] 54.38 [63.00 — 42.00]
Simulation of ICT PET scans
Following the comparison of pre- and post-ICT PET imaging, synthetic
tumours were simulated using PETSTEP [91]. Previously published data
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[36, 65] has proven that statistical models, developed from 100 synthetic tu-
mour objects, are suitable for MTV delineation in diagnostic 18F-FDG PET
imaging. Therefore, adopting the same approach, in this chapter an addi-
tional set of 100 synthetic target tumour objects were simulated, with MTVs,
NIs and TBRs covering the range of values measured from 10 of the FiGaRO
clinical MTVs, thereby generating a new PET imaging dataset consisting of
200 PET scans, known in this chapter as ATLAASICT. The volumes obtained
from the clinical PET scans were in the range 1.59 — 21.25 mL, the range
of NIs were 28 — 63 and the range of TBR values was 0.57 — 3.50. The
contours obtained from the 10 FiGaRO PET scans, used for tumour charac-
teristic comparison, were also used as a basis for the target tumour simula-
tion. Target tumour objects were simulated using PETSTEP, the simulation
process consists of 8 steps [91] as shown in Figure 4.6 and described:
1. A tumour lesion is either added to or replaces the background of a PET
image at a location either specified by a user or at the tumour location.
2. The resulting map is blurred to mimic the Point Spread Function (PSF)
of a PET scanner.
3. Using a radontransform, data is then forward-projected to generate
noise free data.
4. An attenuation map, obtained from a CT image is forward projected to
correct the PET image for attenuation. The attenuated data is scaled
so that the sum of the intensities is equivalent to the total number of
counts being simulated.
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Figure 4.6: The simulation of PET scans using the PETSTEP process. (a)
describes the process for pre-existing objects. (b) describes the process for
new objects. The data shows the sinograms used in the reconstruction of
the PET image and the reconstruction is shown with Poisson noise and ini-
tialisation images used in iterative reconstruction. Figure reproduced, with
thanks, from Berthon et al [91]
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5. Scatter and random annihilation events are added to the resulting im-
age. The distribution of the scatter is generated from the original for-
ward projection of the blurred image; however, the distribution of the
random annihilation events is generated from a uniform background.
6. Noise experienced in PET images acquired from a PET scanner is added
to the simulated data.
7. The produced data can then be reconstructed using an appropriate
reconstruction algorithm.
8. After reconstruction filters may be applied to the reconstructed PET
image.
Figure 4.7a shows the range of MTV and TBR for the FiGaRO trial PET
data and ATLAASORIG before simulation of additional data. Visual com-
parison of the data shows little to no overlap between the characteristics
of the FiGaRO data and ATLAASORIG. However, Figure 4.7b shows that
the simulation of the additional data to create the ATLAASICT dataset has
improved the overlap between the range of MTV and TBR obtained from
FiGaRO trial data and ATLAASORIG. Before simulation of additional data,
Figure 4.8a shows that the range of MTV and NI obtained from the FiGaRO
data and ATLAASORIG had little to no overlap and Figure 4.8b shows that
the overlap between the two datasets improved after simulation of the addi-
tional ATLAASICT scans. Additionally, Figure 4.9a shows that the range of
NI and TBR for the FiGaRO trial PET data and ATLAASORIG had no over-
lap. Whereas, after simulation of the additional scans for the ATLAASICT
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dataset the overlap between the characteristics improved. The ATLAASICT
dataset was used to develop a new decision tree-based statistical model for
ATLAAS.
4.1.5 PET-AS MTV delineation after 1 cycle of ICT
After development of the new statistical model, from the ATLAASICT dataset,
PET-AS algorithms were applied to the clinically acquired PET scans to de-
rive estimated MTVs. MTVs were defined by the PET-AS methods AT, RG,
KM, FCM, GCM, WT and SUVpeak PET-AS methods. SUVpeak was applied
with thresholds ranging from 20% to 80% in increments of 10% (PT20 —
PT80). Further, MTVs were delineated with the ATLAAS statistical models
ATLAASORIG and ATLAASICT. Clustering PET-AS methods were applied
to the PET images with a different number of clusters. KM was applied with
two and three clusters, FCM was applied with two clusters and GCM was
applied with three and four clusters. A total of 336 MTVs were delineated
by different PET-AS methods, resulting in 16 for each patient.
4.1.6 Statistical analysis
In lieu of histopathological specimens or known ground truths, AAPM Task
group 211 [1] recommends reporting DSC when evaluating contours derived
by PET-AS methods and clinicians. In this chapter, therefore, the delineated
PET-AS MTV contours were compared to the manually delineated MTV us-
ing DSC, which was calculated using Matlab 2016b (The MathWorks Inc.,
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(a) Before PETSTEP simulation of ICT PET scans.
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Figure 4.7: The range of MTV and TBR for the FiGaRO trial PET data
and ATLAASORIG and ATLAASICT datasets. Before simulation, the two
datasets had little to no overlap between the characteristics. However, after
simulation of the additional scans the overlap between the datasets improved.
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Figure 4.8: The range of MTV and NI for the FiGaRO trial PET data and
ATLAASORIG and ATLAASICT datasets. Before simulation, the two datasets
had little to no overlap between the characteristics. However, after simulation
of the additional scans the overlap between the datasets improved.
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Figure 4.9: The range of TBR and NI for the FiGaRO trial PET data and
ATLAASORIG and ATLAASICT datasets. Before simulation, the two datasets
had little to no overlap between the characteristics. However, after simulation
of the additional scans the overlap between the datasets improved.
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Natick, Massachusetts, US). The mean DSC, range of DSC and the SD were
also calculated. The performance (DSC) of each PET-AS method was cor-
related with the MTV, TBR and SUVpeak derived from the clinicians’ MTV
contours in order to investigate relationships between the derived tumour
characteristics and the accuracy of each PET-AS method. The MTV in mL
was calculated using in-house software. Statistical differences in DSC distri-
butions were assessed using Kruskal-Wallis and P-values less than 0.05 were
considered to be statistically significant.
4.2 Results
4.2.1 Manual MTV delineation after 1 cycle of chemother-
apy
The mean MTV and range of MTVs, contoured jointly by the nuclear medicine
physician and clinical oncologist, on 18F-FDG PET imaging acquired after
one cycle of chemotherapy, was 6.22 [1.12 — 21.25] mL. The SUVmax range
was 3.51 — 25.00. Figure 4.10 shows contours from four cases, representa-
tive of patients, and the different MTV sizes derived by the nuclear medicine
physician and clinical oncologist included in the FiGaRO trial. In each case,
the user has contoured around the metabolically active region of the tumour,
with varying margins of over contouring in each case. The derived MTV con-
tours, when displayed on co-registered PET/CT scans, also encompass areas
which anatomically are not able to be metabolically active (air, on the CT
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image). Therefore, when deriving the MTV and GTV, functional imaging
and anatomical imaging should be taken into account in order to produce
clinically relevant target volumes.
4.2.2 Comparison between PET-AS MTV and clini-
cian derived MTV
The manually derived MTV’s were compared to the PET-AS derived MTV’s
using DSC. Figure 4.11 shows the mean DSC (+/- SD) for all PET-AS de-
rived MTV, when compared to the manually delineated MTV. ATLAASICT
shows significant improvement in accuracy in comparison to ATLAASORIG.
Additionally, ATLAASICT outperformed all of the other PET-AS methods
included in this chapter. The mean DSC (+/- SD) for the four best per-
forming PET-AS methods, ATLAASICT, PT60, AT, GCM3, and WT was
0.72 (+/- 0.10), 0.61 (+/- 0.20), 0.63 (+/- 0.15), 0.55 (+/- 0.20), 0.60 (+/-
0.21) respectively. A Kruskall Wallace test showed significant difference (P =
0.0003) between the PET-AS MTV and the MTVs delineated by ATLAAS
ICT, PT60, AT, GCM3 and WT PET-AS methods.
Figure 4.12 shows percentage increase in MTV obtained from the PET-AS
methods, AT, ATLAASICT, PT60 and WT when compared to the clinician
derived MTV. The four best performing PET-AS methods delineated MTVs
smaller than the clinician derived MTV in 8 patients and larger in 6 patients.
Specifically, PT60 derived MTV larger than all other included PET-AS meth-
ods in patients 2, 4, 8, 10 and 19. In these cases, the clinician derived MTV
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(a) Patient 1 manual MTV (b) Patient 2 manual MTV
(c) Patient 3 manual MTV (d) Patient 4 manual MTV
Figure 4.10: Contours delineated by a Nuclear Medicine physician and Clini-
cal Oncologist. In each case, the user has contoured around the metabolically
active region of the tumour, with varying margins of over contouring in each
case. The derived MTV contours, when displayed on co-registered PET/CT
scans, also encompass areas which anatomically are not able to be metaboli-
cally active (air, on the CT image). In Figure 4.13 ATLAAS derived contours
are compared to the clinicians’ MTV.
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was less than 2 mL. ATLAASICT and AT delineated the equivalent MTV in
19 patients. Figure 4.13 shows contours delineated by the best performing
method, ATLAASICT, in four patients representative of the patient cohort
in comparison to the manually delineated MTV. An enlarged comparison is
shown within the white box. In patient 3, ATLAAS under contoured the
MTV in comparison to the clinician, whereas in the patient 2 ATLAAS con-
toured a MTV larger than the clinician. In patients 1 and 4, ATLAAS derived
MTVs which are comparable to the the clinician derived MTV. Therefore,
whilst ATLAAS was the best performing PET-AS method in this study, it
should be used as a guide for target volume delineation which can be adapted
and modified according to the treatment planning protocol. ATLAAS has
the potential to inform target volume delineation by demonstrating that the
manually defined MTV can be reduced or should be expanded to include
additional regions of metabolic uptake.
Figures B.1 to B.48 in Appendix B shows the correlations of the PET-AS
methods PT20 — PT80, ATLAASICT, AT, RG, KM with 2 and 3 clusters,
FCM with 2 clusters, GCM with 3 and 4 clusters and WT and the tumour
characteristics SUVpeak, TBR and volume (mL) obtained from the clinician
derived MTV contours. Table 4.2 shows the mean [range] of MTV (mL) and
mean SUVmax of PET-AS derived MTV.
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Figure 4.12: The percentage increase in MTV delineated by PET-AS com-
pared to the MTV of the clinicians
4.3 Discussion
MTV delineation for RT planning, in H&N 18F-FDG PET imaging acquired
after one cycle of ICT is challenging. In IMRT planning especially, errors
in delineation may increase geographical miss [23, 119, 120] because of steep
dose gradients resulting in smaller margins of error. Our analysis of 18F-
FDG tumour characteristics, including the MTV before ICT and after ICT,
demonstrated that tumour characteristics decrease after one cycle of ICT.
Therefore, MTV delineation on imaging acquired before ICT can further
increase the errors in RT planning and therefore can potentially lead to in-
creased dosage to the OAR. The current recommendations to reduce intra
and inter-observer variability, in MTV delineation, are to use fixed window-
ing and viewing levels when delineating the MTV [117, 118]. However, the
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(a) FiGaRO ATLAAS MTV 1 (b) FiGaRO ATLAAS MTV 2
(c) FiGaRO ATLAAS MTV 3 (d) FiGaRO ATLAAS MTV 4
Figure 4.13: ATLAAS derived MTV (blue) compared to manually delineated
MTV (green). A zoomed in view of the derived contours is shown in the white
box. In patient 3, ATLAAS under contoured the MTV in comparison to the
clinician, whereas in the patient 2 ATLAAS contoured a MTV larger than the
clinician. In patients 1 and 4, ATLAAS derived MTV which are comparable
to the the clinician derived MTV.
reduced MTV and metabolic uptake after one cycle of ICT, combined with
standardised viewing parameters, can limit the identification of the tumour
disease extension because of reduced tumour contrast compared to the back-
ground uptake.
One of the aims of this chapter was to externally validate the ATLAAS
segmentation methodology; to achieve this aim, twenty patients recruited
to a phase I feasibility study were analysed. The MTVs derived from six-
teen PET-AS methods, including the ATLAAS segmentation methodology,
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were compared to twenty-one manually delineated MTVs by calculating the
DSC, the percentage differences in MTV and the derived contour SUVmax
values. Analysis of the obtained results showed a significant difference, statis-
tically, in the performance of the MTVs delineated by the PET-AS methods;
with the highest performing PET-AS method in low TBR scenarios, after
the development of a new training dataset, being the ATLAAS segmentation
methodology. Our analysis also demonstrates that AT techniques were found
to be more robust for MTV delineation in comparison to fixed thresholding
techniques. Additionally, tumour characteristics obtained from the manually
delineated MTV and the performance of the PET-AS methods were corre-
lated. The results follow that of other published studies [32, 33, 77], in that
the performance of individual PET-AS methods is dependent upon tumour
and imaging characteristics. However, these results also demonstrate that
the performance of the ATLAAS segmentation methodology is independent
of the same tumour and imaging characteristics and that the performance of
individual automated segmentation methodologies can be enhanced through
the use of machine-learning techniques. Development of the ATLAASICT
statistical model demonstrates that it is possible to optimise / adapt the
ATLAAS segmentation methodology for new treatments and therefore po-
tentially differing PET tracers and anatomical sites.
The results presented in this chapter are limited by a relatively small cohort
(n = 20) of patients, although all recruited as part of the same clinical trial in
OP SCC. Additionally, patients also underwent only one cycle of chemother-
apy; therefore, it was not possible to evaluate the accuracy and robustness of
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the PET-AS methods included in this study against the remaining biological
tissue after multiple cycles of chemotherapy or after fractions of radiotherapy.
This work has been published in Phys Med (2019) [121].
4.4 Conclusion
MTV delineation on 18F-FDG PET imaging acquired after one cycle of ICT
is challenging due to reduced tumour contrast in comparison to background
uptake; however, the machine-learned PET-AS methodology ATLAAS, when
optimised, was accurate for MTV delineation in this low TBR scenario. Fur-
ther, ATLAAS was found to be suitable for MTV delineation on 18F-FDG
PET imaging acquired in centres external to VCC and PETIC. Whilst the
performance of the PET-AS methods were correlated with the tumour char-
acteristics volume (mL), TBR, NI and SUVmax, additional factors and tu-
mour characteristics could influence PET-AS method delineation accuracy.
Therefore, the following chapter investigates the role of morphological fea-
tures extracted from the MTV as classifiers in the development of the AT-
LAAS machine-learned training models.
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Table 4.2: Mean [Range] of Volume (mL), SUVMAX and DSC of the PET-AS
derived MTV
PET-AS Mean MTV
(mL)
Mean
SUVMAX
Mean DSC
(+/- SD)
ATLAASORIG 12.47 [0.22 —
56.48]
10.49 [4.74 —
25.65]
0.42 (+/- 0.21)
ATLAASICT 6.01 [1.30 —
24.00]
10.19 [3.88 —
25.00]
0.72 (+/- 0.10)
PT20 33.67 [4.65 —
98.85]
10.24 [4.23 —
25.00]
0.33 (+/- 0.21)
PT30 21.48 [4.65 —
53.84]
10.24 [4.23 —
25.00]
0.42 (+/- 0.23)
PT40 14.24 [4.65 —
33.06]
10.24 [4.23 —
25.00]
0.53 (+/- 0.27)
PT50 9.61 [4.47 —
21.98]
10.24 [42.23 —
25.00]
0.60 (+/- 0.26)
PT60 8.66 [3.28 —
44.01]
10.17 [3.18 —
25.00]
0.61 (+/- 0.20)
PT70 5.49 [1.49 —
12.13]
10.24 [4.23 —
25.00]
0.60 (+/- 0.16)
PT80 4.32 [1.15 —
12.13]
10.24 [4.23 —
25.00]
0.55 (+/- 0.16)
AT 3.85 [1.20 —
8.75]
10.28 [4.12 —
25.00]
0.63 (+/- 0.15)
RG 69.03 [1.32 —
160.58]
10.21 [4.62 —
25.00]
0.13 (+/- 0.07)
KM2 12.70 [6.01 —
25.16]
10.32 [4.62 —
25.00]
0.54 (+/- 0.28)
KM3 25.38 [11.91 —
6.26]
10.36 [4.62 —
25.00]
0.34 (+/- 0.19)
GCM3 7.96 [1.78 —
19.73]
10.26 [3.98 —
25.00]
0.55 (+/- 0.20)
GCM4 14.12 [4.50 —
32.91]
10.35 [4.62 —
25.00]
0.48 (+/- 0.25)
FCM2 40.36 [4.71 —
96.40]
6.16 [2.51 —
15.83]
0.11 (+/- 0.14)
WT 7.20 [0.54 —
27.55]
10.20 [3.39 —
25.00]
0.60 (+/- 0.21)
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Chapter 5
Impact of morphological
features in the development of
machine learned automated
segmentation training models
Accurate MTV delineation is crucial for the management of cancer, with inac-
curacies leading to increased dose to the OAR [13]. This is especially critical
for IMRT where the margin for error is decreased [23]. As described in Sec-
tion 2.4, the accuracy of PET-AS delineation is influenced by MTV charac-
teristics, including patterns of heterogeneity in the tumour tissue. However,
morphological features, which aim to quantify the MTV shape and surface,
may also be classifiers due to PET-AS algorithms performing differently in
complex shapes. There are currently two techniques used to assess a tumour’s
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response to therapy, one is to compute the longest diameter of the tumour
(Response Evaluation Criteria In Solid Tumours (RECIST) [76]) and the
other is to compute the product of the longest diameter of the tumour and
the maximum perpendicular diameter of the tumour (World Health Organi-
sation (WHO) [122]). For tumours with equivalent MTVs, it is possible that
different longest diameters may be observed and therefore two tumours with
the same volume (mL) have the potential to be classified differently; as a re-
sponder or non-responder. Using this principle, morphological features may
be additional classifiers in the development of training models due to provid-
ing an additional feature dimension when equivalent volumes are observed.
The inclusion of additional feature dimensions is a technique observed in the
development of SVMs to improve hyper-plane definition; therefore, this study
aims to investigate the inclusion of morphological data in a machine learned
training model to improve PET-AS MTV accuracy and to provide an addi-
tional classifier to the ATLAAS segmentation methodology. The materials
& methods to achieve this aim are described in the following sections.
5.1 Materials and Methods
5.1.1 Hardware and software
The hardware and software for the generation and processing of data is de-
scribed in Section 3.1.4.
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(a) 512×512 matrix Drop contour on
1 mm PET
(b) 512×512 matrix Tori contour on
1 mm PET
Figure 5.1: Contours obtained from the training dataset
5.1.2 Training Dataset
The training dataset in this study consists of 211 simulated PET scans with
a total of 260 MTVs. GTs were obtained during the simulation process with
a matrix size of 512×512. The resulting simulated PET image had a matrix
size of 256×256 with voxel dimensions of 2.7×2.7 mm. The training dataset
MTV ranged from 0.02 mL — 184.80 mL with a mean volume of 54.34 mL.
The NI ranged from 2 to 65 with a mean NI of 59.44, whereas TBR ranged
from 0.10 — 4.21 with a mean TBR of 1.98. Figure 5.1 shows contours,
representative of the different tumour complexities and therefore differing
morphological features, within the training dataset with a 512×512 matrix.
Figure 5.1a shows a Drop insert and Figure 5.1b shows a Tori insert. These
shapes were chosen for this study as they had complex geometries and were
identified from previous work [33].
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5.1.3 Validation Dataset
The validation dataset in this study consists of a combination of phantom
and simulated PET scans with 96 MTVs in total. GT contours were ob-
tained from CT imaging, for simulated data GTs were obtained during the
simulation process with a matrix size of 512×512. The validation dataset
MTV ranged from 1.39 mL — 174.96 mL with a mean volume of 32.24 mL.
The NI ranged from 58 to 65 with a mean of 48.01 whereas TBR ranged
from 1.18 to 3.59 with a mean of 1.95. Figure 5.2 to Figure 5.4 show the
overlap between the characteristics of the training and validation dataset.
The MTV and NI of the two datasets overlap in Figure 5.2. Additionally the
MTV and TBR of the two datasets overlaps in Figure 5.3. Furthermore, the
TBR and NI overlap in Figure 5.4. The overlap between the training and
validation dataset characteristics ensures ATLAAS was only evaluated in sce-
narious which it had been trained for. In Chapter 4 a difference in training
and validation dataset characteristics was shown to impact the accuracy of
ATLAAS. Figure 5.5 shows GT contours obtained from CT imaging in the
phantom PET scans in the validation dataset, representative of the differ-
ent tumour complexities and therefore differing morphological features in the
validation dataset. Figure 5.5a shows a GT Pear contour and Figure 5.5b
shows a Tube GT contour. Whilst, similar to to the contours included in the
training dataset (Figure 5.1), the validation dataset contours have distinctly
different geometries and therefore morphological features.
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Figure 5.2: Training and validation dataset MTV and NI. There is good
visual overlap between the training and validation dataset characteristics.
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Figure 5.3: Training and validation dataset MTV and TBR. There is good
visual overlap between the training and validation dataset characteristics.
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Figure 5.4: Training and validation dataset NI and TBR. There is good visual
overlap between the training and validation dataset characteristics.
(a) Pear ground truth (b) Tube ground truth
Figure 5.5: Validation ground truth contours
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5.1.4 Morphological features
Morphological features aim to quantify the surface and shape of a MTV.
Several morphological features (compactness one, compactness two, spheri-
cal disproportion, sphericity and asphericity) quantify the deviation of the
defined volume from a spheroid of the same volume. These features can be
calculated from one another [123] and are therefore highly correlated. How-
ever, they are included in this study for completeness.
Volume
The volume of the tumour calculated from a mesh. Equation 5.1 shows the
IBSI definition for volume, where Vk is the volume of the tetrahedron formed
from the origin at coordinate points (0, 0, 0) with the face k and a, b, c are
the vertex points of the face. Volume is then defined as Equation 5.2 where
V is the MTV defined as the summation of Vk.
Vk =
a · (b× c)
6
(5.1)
V =
Nf c∑
k=1
Vk (5.2)
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Surface area
The surface area of the tumour. Equation 5.3 shows the IBSI definition
for surface area, where A is the surface area calculated by summation of the
surface area of the triangular face area, which is shown in Equation 5.4.
A =
Nf c∑
k=1
Ak (5.3)
Ak =
ab× ac
2
(5.4)
Surface to volume ratio
The surface area divided by the volume of the tumour as defined in Equation
5.5 where A is the surface area and V is the tumour volume.
S2V =
A
V
(5.5)
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Compactness one, Compactness two, Spherical disproportion, Spheric-
ity and Asphericity
These features quantify the deviation of the tumour volume from a repre-
sentative spheroid. Compactness one is defined in Equation 5.6, where V is
volume and A is the surface area. Compactness two is defined in Equation
5.7. Spherical Disproportion is defined in Equation 5.8. Sphericity is defined
in Equation 5.9 and Asphericity is defined in Equation 5.10.
compactnessone =
V
pi1/2A3/2
(5.6)
compactnesstwo = 36pi
V 2
A3
(5.7)
sph.disproportion =
A
(36piV 2)1/3
(5.8)
sphericity =
(36piV 2)1/3
A
(5.9)
asphericity =
( 1
36pi
A3
V 2
)1/3
− 1 (5.10)
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Centre of mass shift
Centre of mass shift (COMShift) is defined as the distance between the tu-
mour volume centroid and the intensity-weighted tumour volume centroid as
defined in Equation 5.11. The centre of the tumour mass is defined in Equa-
tion 5.12. Where, Nv,m is the number of voxels in the mask representing the
tumour and Xc is the voxel point set. The intensity weighted centre of mass
is defined in 5.13, where the position of the voxel in the intensity mask Xc,gl
is weighted by it’s intensity Xgl. Nv,gl is the number of voxels in the intensity
mask. COMShift aims to quantify how far the tumour areas with a higher
metabolic uptake are from the centre of the tumour. A COMShift of 0 means
that the highest area of metabolic uptake is at the centre of the tumour mass,
the higher the COMShift the further the area of highest metabolic uptake is
away from the centre of the tumour mass.
−−−−−−−−→
COMShift =‖ −−−−−−−−−−→tumour.centre−−−−−−−−−−−−→intensity.centre ‖2 (5.11)
−−−−−−−−−−→
tumour.centre =
1
Nv,m
Nv,m∑
k=1
~Xc,k (5.12)
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−−−−−−−−−−−→
intensity.centre =
∑Nv,gl
k=1 Xgl,k
~Xc,gl,k∑Nv,gl
k=1 Xgl,k
(5.13)
Maximum 3D diameter
Distance between the two most distant vertices in the mesh defined in Equa-
tion 5.14.
Max.3D.Diam = max
(
‖ ~Xvx,k1− ~Xvx,k2 ‖2
)
, k1 = 1, ..., N k2 = 1, ..., N
(5.14)
Major, minor and least axis length
Principle component analysis is used to determine the largest, second largest
and smallest tumour axis. Major axis length is defined in Equation 5.15.
Minor axis length is defined in Equation 5.16 and least axis length is defined
in Equation 5.17. λ is the eigenvalue of the eigenvector vector output from
the principle component analysis of the tumour.
Major = 4
√
λmajor (5.15)
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Minor = 4
√
λminor (5.16)
Least = 4
√
λleast (5.17)
Elongation and Flatness
Elongation is the ratio of the length of the tumour against the width of the
tumour as defined in Equation 5.18 and flatness is the ratio of the major axis
length and the least axis length as defined in Equation 5.19.
Elongation =
√
λminor
λmajor
(5.18)
Flatness =
√
λleast
λmajor
(5.19)
Volume Density and Area Density
Volume density is the ratio of the tumour volume and the volume of the
bounding box, whereas the area density is the ratio of the surface area of the
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tumour volume to surface area of the bounding box as defined in Equations
5.20 and 5.21, where bb is the boundary box type. In this study, the boundary
box was defined using 3 different approaches, axis alignment, approximation
of the enclosing ellipsoid and a convex hull.
v.dens =
V
Vbb
(5.20)
a.dens =
A
Abb
(5.21)
The morphological features were implemented as part of the IBSI initiative
for the standardisation of the extraction of radiomic features from medical
images [123,124].
5.1.5 ATLAAS training model development
For a given field of view (FOV), a CT image has matrix dimensions of
512×512 voxels, with voxel dimensions of 0.98×0.98×3 mm. In compar-
ison, for the same FOV, PET image matrices are typically 128×128 vox-
els or 256×256 voxels dependent upon the scanner and reconstruction set-
tings [125]. PET images with matrix dimensions of 256×256 have voxel
dimensions of 2.7×2.7×3 mm. The resolution (matrix and voxel dimension)
of PET imaging, is limited by the physics of the PET scanner; including, the
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limited size of the PMTs and size of the detectors. Therefore, due to the
low finite spatial resolution, PET imaging is subject to the partial volume
effect (PVE) [126–128] which may affect the quantification of morphological
features. The PVE consists of two distinct imaging processes, the tissue frac-
tionation effect and 3D image blurring [126]. PVE in PET imaging can be
seen in Figure 5.6 as a CT contour is transferred to PET images interpolated
to differing resolutions including the resolution of the CT where Figure 5.6a
to 5.6e shows the CT contour transferred to 1, 2, 3 and 4 mm interpolated
PET imaging. The CT contour is spherical and transferring the contour to
lower image resolutions results in the degradation of the contour; degradation
increases the number of imaging artefacts, including straight lines (consisting
of multiple voxels) and jagged edges with acute changes in contour direction.
In comparison, interpolating the PET image to a 1 mm voxel dimension
results in the same PET contour, as obtained from the CT imaging. AT-
LAAS training models were developed by interpolating the PET images in
the training dataset to spatial resolutions of 4 mm, 3 mm and 2 mm isotropic
voxels. A further training dataset was developed by interpolating the PET
images in the training dataset to a x and y voxel dimensions of 1 mm with
a slice thickness of 3 mm. A resolution of 1×1×3 mm was chosen, instead
of a 1 mm isotropic voxel dimension, due to being equivalent to the highest
resolution of CT image acquired clinically in our centre (0.98×0.98×3 mm
voxel dimension). A voxel dimension of 1×1×3 mm was chosen instead of a
0.98×0.98×3 mm was chosen to provide equal spacing and distance between
the other training datasets (1 mm spacing). Additionally, interpolation to 1
mm isotropic voxel dimension in PET imaging is computationally expensive,
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interpolation without an external GPU takes ≈ 30 min — 1 hr dependent
upon the number of slices in the PET image and PET-AS delineation at a
1 mm isotropic voxel resolution is time consuming, taking up to ≈ 2 hr de-
pendent upon the PET-AS method and number of slices in the PET image.
The specifications for the computer used for 1 mm isotropic voxel dimension
interpolation are a 3.2 Ghz Intel Core i5 computer, with 16GB of RAM and
a 2GB dedicated AMD Radeon R9 M380 GPU. Timing calculations were
performed using the ‘tic’ and ‘toc’ functions available within the MATLAB
2016b programming environment.
The training models were developed for each of the morphological features
described in Section 5.1.4 at each voxel resolution (1×1×3 mm, 2×2×2 mm,
3×3×3 mm and 4×4×4 mm), resulting in 88 training models in total. These
resolutions and morphological features were chosen for completeness.
5.1.6 Interpolation of PET imaging
The Oxford English Dictionary defines the noun interpolation as the ac-
tion of introducing or inserting among other things or between the members
of any series [129]. Further to this, interpolation is defined as the process
of determining the value of a function between two points at which it has
prescribed values. There are a variety of interpolation techniques including
linear, spline, nearest neighbour and cubic interpolation. Interpolation can
occur in 2D and 3D directions, nominally known as tri-linear or tri-cubic
interpolations in 3D or bi-linear and bi-cubic interpolation in 2D.
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(a) CT (b) 1 mm PET
(c) 2 mm PET (d) 3 mm PET (e) 4 mm PET
Figure 5.6: CT GT contour (orange) transferred to PET images interpolated
to 1, 2, 3 and 4 mm voxel dimensions, demonstrating PVE. For comparison,
a spherical contour (red) representing a perfect sphere was overlaid on the
PET/CT images.
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Linear Interpolation
The estimation of the value of an unknown data point between the values of
two known data points as a function of a straight line is known as linear in-
terpolation. Equation 5.22 defines linear interpolation mathematically whilst
Figure 5.7 visualises the linear interpolation process. y is the unknown value
at point x and y0 and y1 are the known values at points x0 and x1. Given
the values of y0 = 1, y1 = 2, x0 = 0, x1 = 2 and we want to find the value of
y at point x = 1. Equation 5.23 to 5.26 shows the calculation of y at point
x = 1.
y =
y0(x1− x) + y1(x− x0)
(x1− x0) (5.22)
p1 = y0(x1− x)
= y0x1− y0x
= 2− 1
= 1
(5.23)
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p2 = y1(x− x0)
= y1x− y1x0
= 2− 0
= 2
(5.24)
p3 = (x1− x0)
= 2− 0
= 2
(5.25)
y =
p1 + p2
p3
=
1 + 2
2
= 1.5
(5.26)
2D Linear interpolation is an extension of linear interpolation. Linear inter-
polation is applied first in one direction between a set of four rectangular
known data points and then applied in the orthogonal direction secondly.
Whether linear interpolation is first applied in the x or y direction is respec-
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Figure 5.7: Linear interpolation between the value of two known data points
to find the estimated value of the unknown data point.
tive of implementation choice. 3D linear interpolation is a further extension
of 2D linear interpolation. As with 2D linear interpolation, whether inter-
polation occurs first in the x or y is respective of implementation design.
However, linear interpolation in the z direction occurs once x, y data points
have been interpolated.
Cubic Interpolation
Cubic interpolation in comparison to linear, bi-linear and tri-linear interpo-
lation produces a smooth continuous estimation between known data points.
Cubic interpolation requires the values of four known data points with two
data points outside of two points to interpolate between. Cubic interpola-
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tion therefore requires the use of four equations to define the value of the
unknown data point x. These are defined in equations 5.27, 5.28, 5.29 with
the final value of the unknown data point x shown in equation 5.30. y0, y1,
y2, y3 are the values of the designated four known data points to interpolate
between. x is the point of interpolation with a value of 0 equaling the first
data point and a value of 1 equaling the second data point to be interpolated
between.
a0 = y3− y2− y0 + y1; (5.27)
a1 = y0− y1− a0; (5.28)
a2 = y2− y0; (5.29)
a0× x× x2 + a1× x2 + a2× x+ y1 (5.30)
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Nearest Neighbour Interpolation
Nearest neighbour interpolation is the least computationally expensive form
of interpolation and the most intuitive to implement. Nearest neighbour
interpolation simply assigns the data point x the value of closest data point.
The distance between points can be computed using euclidean distance. In
1D Nearest Neighbour interpolation the algorithm takes into account two
data points. 2D and 3D nearest neighbour extend this into the x, y and
z directions with nearest neighbour being applied in the x or y directions
first dependent upon the design of the implementation. In effect, nearest
neighbour interpolation up samples an image to a high resolution without
estimation of unknown data points.
Spline Interpolation
Spline interpolation fits a smooth curve through all of the known data points.
The interpolation method chosen in this study was 3D linear interpolation
(tri-linear), as it is considered to be data consistent and is computationally
inexpensive.
5.1.7 Segmentation algorithms
The ATLAAS segmentation methodology incorporating the PET-AS meth-
ods, AT, KM clustering with 2, 3 and 4 clusters, GCM clustering with 3 and
4 clusters and WT methods was investigated in this study. For a detailed
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description of ATLAAS see Chapter 2 Section 2.4.
5.1.8 Statistical Analysis
The 88 developed ATLAAS training datasets were used to derive MTVs
on the validation dataset. The boundary region for applying ATLAAS to
the validation dataset was defined as a 1 cm expansion of the GTV. The
validation dataset was interpolated to the resolution of the training dataset.
Therefore, a training dataset developed on a 4 mm isotropic voxel dimension
was applied to a validation dataset with a 4 mm isotropic voxel dimension
and a training dataset developed on a 1 mm XY voxel dimension with a
3 mm slice thickness was applied to a validation dataset with a 1 mm XY
voxel dimension and 3 mm slice thickness. All training datasets consisted
of the same PET MTVs and all validation datasets consisted of the same
PET MTVs. Further to comparing the developed ATLAAS training models,
the PET-AS methods AT, WT, KM with 2, 3 and 4 clusters and GCM
with 3 and 4 clusters were applied to the validation dataset GT volumes.
The resulting ATLAAS and PET-AS derived MTVs were compared to the
highest-resolution GT volume available using DSC, as defined in Equation
2.3. Significant differences in DSC were assessed using Kruskal-Wallis (P <
0.05).
For each morphological feature included in the training dataset a one-tailed
mann-whitney U test was used to test for significant improvement in the accu-
racy of the training model from a low-spatial resolution PET (4 mm isotropic
voxel) to an increased spatial resolution PET (3 mm, 2 mm isotropic voxel
136
resolution and a 1 mm XY voxel resolution with a 3 mm slice thickness). A
Kruskal-Wallis test was used to test for significant differences in the accuracy
of the training models when additional morphological features were included
in the training model. P values less than 0.05 were considered statistically
significant. Statistical analysis was performed using a Matlab 2016b license.
Image processing and statistics toolbox licenses were installed as well.
5.1.9 Results
A training dataset of 211 18F-FDG PET scans was interpolated to four differ-
ing voxel resolutions. 21 morphological features were included as additional
parameters to the ATLAAS training model, providing in total 88 ATLAAS
training models including the original ATLAAS training model developed
using NI, TBR and volume (mL). The 88 ATLAAS training models were
used to delineate an estimated MTV on the validation dataset consisting of
260 PET GTV’s. ATLAAS derived contours were assessed visually and by
calculating the DSC between the ATLAAS contour and the GT. Figure 5.8
on page 140 shows the median and range of DSC for ATLAAS applied to the
validation dataset when trained with the parameters NI, MTV and TBR.
Interpolating PET images in the training dataset and validation dataset im-
proved the mean DSC for the parameters, NI, TBR and MTV by 19%, with
a mean DSC for 4 mm PET imaging of 0.59 [0.16 — 0.86] and a mean DSC
for 1 mm PET imaging of 0.78 [0.46 — 0.93].
In all of the developed models, interpolating PET imaging from a 4 mm
isotropic voxel to a 1 mm XY, 3 mm slice thickness resulted in a mean im-
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provement in DSC across all of the developed models of 20 %. Box plots
showing the median, minimum and maximum DSC, for all of the developed
models, are in Appendix C C.1. The best performing training model included
the tumour and PET characteristics, NI, TBR, MTV and one of the follow-
ing morphological features: compactness one, compactness two or sphericity.
The models developed with compactness one, compactness two and spheric-
ity each had a mean DSC of 0.81 with a range of 0.46 — 0.93. The correlation
of the features compactness one, compactness two and sphericity are shown
in Figures 5.9, 5.10 and 5.11, with the p-values and spearman rank corre-
lation values of 0.00 and 1.00 respectively for each comparison. P-values of
less than 0.05 reject the hypothesis that there is no correlation between the
compared feature values.
Figure 5.12 on page 142 shows cases which had a greater than 200% difference
in the MTV derived by ATLAAS and the MTV of the GT contour on the
validation dataset and Figure 5.13 on page 143 shows cases which had a less
than 200% difference in the MTV derived by ATLAAS and the MTV of the
GT contour on the validation dataset. Descriptive statistics for the MTV of
the contours derived by ATLAAS with the parameters NI, TBR and volume
(mL) and the GT contours are shown in Table 5.1 on page 140. The mean
MTV of the GT was 32.24 mL [1.39 — 174.96 mL].
Figure 5.14 on page 144 shows the box plots for the median, minimum and
maximum DSC for the PET-AS methods AT, KM clustering with 2, 3 and 4
clusters, GCM clustering with 3 and 4 clusters and WT PET-AS methods.
Independent Kruskal-Wallis tests showed a significant difference at the 5 %
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significance level in the DSC of AT, WT, KM2, KM3, KM4, GCM3 and
GCM4 PET-AS methods when applied to PET images at 4, 3 and 2 mm
isotropic voxel dimensions and 1 mm XY voxel dimension with a 3 mm slice
thickness (P-values < 0.05).
Figure 5.15 on page 145 shows ATLAAS applied to PET images with a 1
mm XY with a 3 mm slice thickness and 2 mm, 3 mm and 4 mm isotropic
voxel dimensions compared to the GT contour obtained from the CT image.
Figure 5.15a shows that the ATLAAS contour derived on 1 mm PET imaging
was up to 2.90 mm under-contoured when compared to the GT. Figure 5.15b
shows that the ATLAAS contour derived on 2 mm PET imaging was up to
1.95 mm under-contoured when compared to the GT. Figure 5.15c shows
that the ATLAAS contour derived on 3 mm PET imaging was up to 2.70
mm under-contoured when compared to the GT. Figure 5.15d shows that
the ATLAAS contour derived on 4 mm PET imaging was up to 2.98 mm
over-contoured when compared to the GT.
Figures 5.16 and 5.17 on page 146 and page 147 respectively, show the con-
tours derived by the PET-AS methods, AT, WT, KM2, KM3, KM4, GCM3
and GCM4 PET-AS methods in a pear phantom insert PET image inter-
polated to a 1 mm XY voxel dimensions with a 3 mm slice thickness and
Figure 5.18 on page 148 shows the contours derived by the PET-AS method
KM with 2 clusters. KM2 was the highest-performing individual PET-AS
method on 1 mm XY voxel dimensions with a 3 mm slice thickness, with a
mean DSC of 0.83.
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Figure 5.8: DSC of ATLAAS with parameters NI, TBR and MTV applied
to the validation dataset
Table 5.1: Descriptive statistics for the volumes derived by ATLAAS with
the parameters NI, TBR and volume and the GT contour.
Ground
Truth
(mL)
ATLAAS
one mm
(mL)
ATLAAS
two mm
(mL)
ATLAAS
three mm
(mL)
ATLAAS
four mm
(mL)
Mean 32.24 51.28 52.07 49.83 45.83
Minimum 1.39 2.18 1.73 1.73 3.07
Maximum 174.96 195.05 195.11 175.45 163.07
Standard
deviation
38.34 57.76 55.22 52.42 49.25
Median 19.87 33.85 33.96 30.98 26.88
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Figure 5.9: The correlation of compactness one and sphericity ground truth
feature values in the validation dataset.
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Figure 5.10: The correlation of compactness one and compactness two ground
truth feature values in the validation dataset.
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Figure 5.11: The correlation of compactness two and sphericity ground truth
feature values in the validation dataset.
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Figure 5.12: Cases with a greater than 200% difference in the volume derived
by ATLAAS with parameters NI, TBR and MTV and the volume of the GT
contour.
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(b) GCM3
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(c) GCM4
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(d) KM2
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(e) KM3
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(f) KM4
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Figure 5.14: DSC of PET-AS applied to PET images with 4 mm, 3 mm, 2
mm and 1 mm XY, 3 mm Z voxel dimensions
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(a) ATLAAS contour on 1 mm PET (b) ATLAAS contour on 2 mm PET
(c) ATLAAS contour on 3 mm PET (d) ATLAAS contour on 4 mm PET
Figure 5.15: ATLAAS derived MTV in comparison to the high-resolution GT
contour in a spherical object. ATLAAS contour is red and the GT contour
is blue with measured distances between the two contours being 2.90 mm (1
mm PET), 1.95 mm (2 mm PET), 2.70 mm (3 mm PET), 2.98 mm (4 mm
PET). Distances between ATLAAS and the GT contour to on 1 mm PET
imaging.
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(a) GCM3 (b) GCM4
(c) WT (d) KM2
Figure 5.16: PET-AS derived MTV in comparison to the high-resolution GT
contour in a Pear PET insert. The GT contour is turquoise, GCM3 (purple),
GCM4 (dark green), WT (gold) and KM2 (green)
.
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(a) KM3 (b) KM4
(c) AT
Figure 5.17: PET-AS derived MTV in comparison to the high-resolution GT
contour in a Pear PET insert. The GT contour is turquoise, KM3 (pink),
KM4 (lime green) and AT (purple)
.
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(a) KM2 1 mm (b) KM2 2 mm
(c) KM2 3 mm (d) KM2 4 mm
Figure 5.18: KM2 derived MTV in comparison to the high-resolution GT
contour in a Pear PET insert. The GT contour is turquoise and KM2 is
green.
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5.2 Discussion
Investigating the role of additional classifiers in the development of machine-
learning PET-AS training models is important for accurate MTV delineation.
Additional classifiers, including morphological features, may improve the de-
lineation of complex tumours. Previous work has shown that tumour charac-
teristics and PET imaging characteristics influence the performance of PET-
AS methods. Therefore, the use of PET-AS methods in RT planning may
have an impact on the dosage to the OAR or patient risk-stratification, or
OS. This work aimed to investigate the currently available morphological
features which describe a tumours shape for inclusion in machine-learned
DTs. Therefore, 22 morphological features were used to develop DTs at four
different voxel dimensions to assess the influence of the PVE on the computa-
tion of morphological features. The performance of each developed training
model was analysed using the DSC.
The results of this experiment show that morphological features are classi-
fiers, in addition to those already known, in the development of machine-
learned models for accurate MTV delineation. This is due to individual
PET-AS algorithms performing differently in complex shapes. Further, the
results show that the resolution of the PET image influences the accuracy of
PET-AS delineation. In this study, delineated MTVs were compared against
high-resolution GTs derived on a 1 mm XY voxel dimension with a 3 mm slice
thickness; however, training models developed with a 2 mm isotropic voxel
dimension had a reduced performance in comparison to models developed
at a 3 mm isotropic voxel resolution. The reduction in model accuracy is
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caused by the comparison of the 2 mm isotropic contour to the GT contour,
which requires the estimation of the contour on the 3 mm slice thickness.
In comparison, a MTV delineated on a 1 mm slice thickness or a 3 mm
slice thickness does not require estimation of the contour at the 3 mm slice
thickness. The best performing training model included the tumour and
PET characteristics, NI, TBR, MTV and one of the following morphologi-
cal features: compactness one, compactness two or sphericity. Compactness
one, two and sphericity produced the same DSCs in the validation dataset
and their feature values were highly correlated (Spearman rank correlation
= 1.00, p-value = 0.00), therefore they can be used in the training model
interchangeably.
Seven advanced individual PET-AS methods were also included in this study
and applied to the validation dataset PET imaging which was interpolated
to a 1 mm XY voxel dimension with a 3 mm slice thickness and 2 mm, 3 mm
and 4 mm isotropic voxels. Interpolation to a 1 mm XY voxel dimension with
a 3 mm slice thickness improved the performance of PET-AS delineation for
individual PET-AS methods as well as the ATLAAS segmentation method-
ology. This work also demonstrates the degradation of a contour transferred
from a high resolution CT PET to a lower resolution PET image. Therefore,
interpolation of the PET should be to the highest resolution of the imaging
modality available at the time of acquisition.
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5.3 Conclusion
The morphological features compactness one, two and sphericity are addi-
tional classifiers compared to the already known parameters, MTV, TBR
and NI. However, MTV delineation accuracy with PET-AS methods is de-
pendent upon the voxel dimensions of the PET image. Interpolation of the
PET image to a higher resolution improved PET-AS MTV delineation. In
RT planning, improved MTV delineation accuracy is crucial for the stan-
dardisation of MTV delineation, as well as to reduce dosage to the OAR.
This is especially critical in IMRT where steep dose gradients decrease the
margin for error. In the following chapter, the results and conclusion drawn
from this chapter, are related to the conclusions drawn throughout this body
of work and within the context of the literature.
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Chapter 6
Discussion & Conclusion
6.1 Discussion
Chapter 1 provides an introduction to RT of cancer and outlines the hy-
pothesis for this body of work. The hypothesis was, the machine-learned
PET-AS methodology called ATLAAS would have a higher level of accuracy
in comparison to advanced PET-AS methods, for MTV delineation. In order
to investigate this hypothesis fully, the aims and objectives of the TITAN
project were:
• Improve the performance of the ATLAAS segmentation methodology.
• Externally validate the performance of the ATLAAS segmentation method-
ology.
• Investigate the effect of PET-AS methods on the development of prog-
nostic models, therefore demonstrating the requirement for an agreed
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upon PET-AS methodology in planning RT.
• Investigate the role and robustness of the ATLAAS segmentation method-
ology for intra-treatment MTV delineation.
• Investigate the impact of morphological features on the performance of
ATLAAS.
In order to identify gaps within current knowledge, a literature review of
MTV delineation using PET-AS methods was undertaken and presented in
Chapter 2. This identified that whilst PET-AS methods had been investi-
gated for suitable MTV delineation, the impact they have on patient risk
stratification when curating large datasets was unknown. Therefore, Chap-
ter 3 aimed to address this issue and established a need for an agreed upon
method for MTV delineation. This was accomplished by applying 9 PET-AS
methods to the same clinical data, in order to derive different MTVs. Prog-
nostic models were developed from radiomic features extracted from the de-
rived MTVs and were used to risk stratify patients. The results showed that
sub-groups of patients have the potential to be denied beneficial treatment
and sub-groups of patients may recieve unecessary and futile treatments.
These treatments could reduce the quality of life of a patient.
In the literature review (Chapter 2), it was also identifed that the role and
robustness of PET-AS methods for suitable MTV delineation had not been
investigated in intra-treatment PET imaging. Therefore, Chapter 4 was de-
signed to address this issue and the aim was achieved by delineating MTVs
on patient’s PET scans, which were acquired after one cycle of ICT. The
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PET scans were identified from a phase I, multi-centre feasibility trial called
FiGaRO. The results of Chapter 4 show that the performance of machine-
learning algorithms in scenarios they have not been trained for is limited.
However, the performance can be improved by the simulation of additional
data. Additionally, the results show that the performance of ATLAAS was
higher in-comparison to the advanced and simpistic PET-AS methods in-
cluded in the chapter. Chapter 4 also achieves the aim of externally vali-
dating ATLAAS by using data identified from a multi-centre feasibility trial.
Further, the results support the hypothesis that ATLAAS has a higher level
of accuracy in comparison to advanced PET-AS methods.
Additionally, in order to meet the aim of improving the performance of the
ATLAAS PET-AS methodology, Chapter 5 had the objective of investigat-
ing the impact of morphological features on the performance of ATLAAS.
To achieve this, 88 training models were developed. The models were devel-
oped by individually including 22 morphological features as classifiers. The
morphological features were extracted from PET imaging interpolated to 4
different voxel dimensions. The results of Chapter 5 show that interpolating
PET to higher resolutions improves the performance of PET-AS methods and
that morphological features potentially can improve machine-learned MTV
delineation.
A range of PET-AS methods, including the machine-learned PET-AS method-
ology ATLAAS have been evaluated and compared throughout this project;
with the critical analysis techniques and domain knowledge acquired (during
the project) being used to optimise the performance of the ATLAAS segmen-
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tation methodology. The optimisation of ATLAAS was achieved through the
development of new training datasets, which are optimised for low TBR sce-
narios (Chapter 4). Additionally, in Chapter 5, morphological features were
investigated for influencing PET-AS performance and the significant features
highlighted during the chapter were included in the development of additional
new high-resolution training datasets.
In 2014, the IAEA published a report stating that no single PET-AS method
could be recommended for accurate MTV delineation [31]; more recently, a
report was published by the AAPM Task Group No 211 [1] stating that
no single PET-AS method can be recommended for accurate MTV delin-
eation; further, the report states that machine-learning techniques are show-
ing promise for accurate MTV delineation. The analysis of the results pre-
sented throughout this body of work support the joint recommendations of
the AAPM Task Group No 211 [1] and the IAEA [31] in that no single
PET-AS method is suitable for MTV delineation in all cases. Addition-
ally, this body of work supports the AAPM task group’s recommendations
that machine-learning techniques are showing promise for accurate MTV
delineation by showing that additional (morphological features) classifiers,
higher-resolution PET scans and optimisation of training datasets can im-
prove machine-learning PET-AS MTV delineation. This work has shown
that in comparison to advanced PET-AS algorithms and simplistic PET-AS
algorithms, the machine-learned ATLAAS segmentation methodology was
found to be more accurate for MTV delineation (Chapter 4).
Whilst this body of work represents a comprehensive evaluation of the AT-
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LAAS segmentation methodology, ATLAAS has not been compared to other
machine-learning methodologies including random forest, SVM or deep-learned
neural networks. Currently these technologies are being developed in our cen-
tre and therefore future work aims to evaluate the efficacy and performance of
these methods. Deep-learned neural networks may prove in investigations to
have a higher accuracy in comparison to traditional PET-AS techniques and
less complex machine-learned PET-AS segmentation methodologies. How-
ever, the development and training of the deep-learned neural networks re-
quires extensive hardware requirements in the form of external or dedicated
GPUs or multi-core / processor servers. Therefore, these techniques may
be of limited use in the clinical environment where the development of new
training datasets or neural networks may be required, dependent upon the
needs of the clinic. Further, this evaluation is critical as in the 2017 Medi-
cal Image Computing and Computer Assisted Intervention (MICCAI) PET
tumour segmentation challenge [130], convolution neural networks were the
best performing PET-AS method.
The MICCAI challenge in 2017 was the first extensive evaluation of PET-AS
methods involving 16 teams and a total of 10 PET-AS methods. However
it does not provide a thorough analysis of all available PET-AS methods in
all clinical scenarios, anatomical locations or all radiotracers. There is still a
need, therefore, for a comprehensive and standardised dataset for the accu-
rate evaluation of PET-AS methods [131], across all anatomical locations and
the differing radiotracers in PET imaging. The development of a benchmark
dataset will allow for the development of an agreed upon PET-AS method
156
which is increasingly important as adaptive RT and RT planning after ICT
become more popular and increasingly used techniques. An agreed upon
PET-AS method for MTV delineation also has implications for prognostic
research.
Increasingly, prognostic research is being investigated to ensure patients are
treated appropriately and to improve patient OS. However, prognostic re-
search requires the curation of large datasets which are subject to inter and
intra-observer variability of the MTV. In Chapter 3, the role of PET-AS
methods for the curation of datasets and the development of prognostic mod-
els was investigated. The results demonstrate that a agreed upon approach
to the delineation of the MTV is required as differences in MTV delineation
can cause patients to change risk-stratification and therefore be potentially
treated with unnecessary and aggressive therapies. The results of the inves-
tigation in Chapter 3 are strengthened by a large patient cohort n = 472.
In Chapter 3 radiomic features were extracted using SUV bins of 0.5 units.
However, a further extension of the study could investigate how different
discretisation methods influence the significance of radiomic features in the
development of prognostic models and subsequent impact on risk stratifica-
tion and OS in patients with OC.
With increasing interest in multi-modality treatment pathways it is crucial
that the MTV is delineated accurately in planning PET/CT imaging ac-
quired during treatment in order to reduce inter and intra-observer variabil-
ity, ensure conformal dose to the MTV and to reduce dosage to the OAR.
Therefore, 16 PET-AS methods, including ATLAAS were investigated for
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accurate MTV delineation in a range of low TBR scenarios and MTVs. Of
the 16 PET-AS methods, only ATLAAS showed acceptable performance in
the range of scenarios. Therefore, ATLAAS has been proposed for the stan-
dardised delineation (agreed upon PET-AS delineation method) of the MTV
during treatment. However, the results of the investigation in Chapter 4 are
limited by a small patient cohort (n = 21). The external validation of the
ATLAAS segmentation methodology undertaken as part of this body of work
is crucial for acceptance of ATLAAS, as an agreed upon method for MTV
delineation in the clinical environment (Chapter 4).
Throughout this thesis additional training datasets were generated using the
PETSTEP simulator. When PETSTEP is supplied with a PET scan with
specific radiotracer characteristics (for example, 18F-FDG), the resulting sim-
ulated PET scans exhibit the same tumour radiotracer uptake characteris-
tics. Therefore, by supplying PETSTEP with a PET scan with differing
radiotracer characteristics it is possible to simulate additional radiotracers.
Due to the increased tumour characteristics that radiotracers are dependent
upon, in order to reduce overfitting of the training model, ATLAAS poten-
tially requires a separate training dataset for each specific radiotracer. This
is especially important as the best performing PET-AS methods in 18F-FDG
PET imaging may be different in 11C-Ch or 15O based PET scans. In compar-
ison, when applying ATLAAS to different anatomical sites, the anatomical
location of the tumour (e.g H&N, OC or prostate) can be included in the
development of the ATLAAS decision trees as a categorical classifier in order
to improve PET-AS accuracy. Additionally, different treatments may require
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different image processing techniques before MTV delineation. For example,
inflammation caused by RT has the potential to impact the most appropri-
ate PET-AS method for accurate MTV delineation when RT is re-planned
(adaptively) throughout treatment.
6.2 Conclusion
The project described in this thesis aimed to investigate the performance of
advanced automated segmentation methods for accurate MTV delineation.
The following results were achieved throughout the duration of this project:
• Improved performance of the ATLAAS segmentation methodology in
low TBR scenarios by the development of new datasets.
• Improved performance of the ATLAAS segmentation methodology by
including additional tumour characteristics as classifiers.
• External validation of the performance of the ATLAAS segmentation
methodology.
• Demonstrated improved performance of the ATLAAS segmentation
methodology in comparison to 16 PET-AS methods for intra-treatment
MTV delineation.
• Demonstrated PET-AS MTV delineation influences the development
of prognostic models, therefore demonstrating the requirement for an
agreed upon PET-AS methodology in planning RT and in the devel-
opment of prognostic models.
159
• Demonstrated interpolation of PET imaging to a higher resolution,
before MTV delineation, improves the accuracy of advanced PET-AS
and machine-learned PET-AS.
The results presented in Chapters 4 to 5 demonstrate that the performance of
the ATLAAS segmentation methodology is greater than the advanced PET-
AS methods investigated and the results presented in Chapter 3 highlight the
requirement for an agreed upon MTV delineation method. The work pre-
sented in this thesis has also paved way for further research into the applica-
tion of the ATLAAS segmentation methodology in the planning and delivery
of radiotherapy treatments at the Velindre Cancer Centre. Specifically, in
a multi-centre clinical trial where the ATLAAS segmentation methodology
will be used to prospectively delineate the MTV for adaptive radiotherapy
treatment planning and delivery [132].
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Appendix B
PET-AS MTV delineation in
low tumour to background
ratio PET
B.1 Correlation of PET-AS methods DSC and
Clinician derived radiomic features
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Figure B.1: Correlation of ATLAAS DSC and clinician derived MTV
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Figure B.2: Correlation of ATLAAS DSC and Clinician derived SUVPEAK
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Figure B.3: Correlation of ATLAAS DSC and Clinician derived TBR
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Figure B.4: Correlation of PT20 DSC and Clinician derived MTV
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Figure B.5: Correlation of PT20 DSC and Clinician derived SUVPEAK
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Figure B.6: Correlation of PT20 DSC and Clinician derived TBR
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Figure B.7: Correlation of PT30 DSC and Clinician derived MTV
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Figure B.8: Correlation of PT30 DSC and Clinician derived SUVPEAK
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Figure B.9: Correlation of PT30 DSC and Clinician derived TBR
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Figure B.10: Correlation of PT40 DSC and Clinician derived MTV
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Figure B.11: Correlation of PT40 DSC and Clinician derived SUVPEAK
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Figure B.12: Correlation of PT40 DSC and Clinician derived TBR
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Figure B.13: Correlation of PT50 DSC and Clinician derived MTV
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Figure B.14: Correlation of PT50 DSC and Clinician derived SUVPEAK
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Figure B.15: Correlation of PT50 DSC and Clinician derived TBR
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Figure B.16: Correlation of PT60 DSC and Clinician derived MTV
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Figure B.17: Correlation of PT60 DSC and Clinician derived SUVPEAK
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Figure B.18: Correlation of PT60 DSC and Clinician derived TBR
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Figure B.19: Correlation of PT70 DSC and Clinician derived MTV
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Figure B.20: Correlation of PT70 DSC and Clinician derived SUVPEAK
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Figure B.21: Correlation of PT70 DSC and Clinician derived TBR
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Figure B.22: Correlation of PT80 DSC and Clinician derived MTV
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Figure B.23: Correlation of PT80 DSC and Clinician derived SUVPEAK
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Figure B.24: Correlation of PT80 DSC and Clinician derived TBR
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Figure B.25: Correlation of AT DSC and Clinician derived MTV
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Figure B.26: Correlation of AT DSC and Clinician derived SUVPEAK
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Figure B.27: Correlation of AT DSC and Clinician derived TBR
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Figure B.28: Correlation of FCM2 DSC and Clinician derived MTV
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Figure B.29: Correlation of FCM2 DSC and Clinician derived SUVPEAK
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Figure B.30: Correlation of FCM2 DSC and Clinician derived TBR
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Figure B.31: Correlation of GCM3 DSC and Clinician derived MTV
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Figure B.32: Correlation of GCM3 DSC and Clinician derived SUVPEAK
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Figure B.33: Correlation of GCM3 DSC and Clinician derived TBR
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Figure B.34: Correlation of GCM4 DSC and Clinician derived MTV
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Figure B.35: Correlation of GCM4 DSC and Clinician derived SUVPEAK
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Figure B.36: Correlation of GCM4 DSC and Clinician derived TBR
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Figure B.37: Correlation of KM2 DSC and Clinician derived MTV
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Figure B.38: Correlation of KM2 DSC and Clinician derived SUVPEAK
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Figure B.39: Correlation of KM2 DSC and Clinician derived TBR
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Figure B.40: Correlation of KM3 DSC and Clinician derived MTV
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Figure B.41: Correlation of KM3 DSC and Clinician derived SUVPEAK
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Figure B.42: Correlation of KM3 DSC and Clinician derived TBR
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Figure B.43: Correlation of RG DSC and Clinician derived MTV
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Figure B.44: Correlation of RG DSC and Clinician derived SUVPEAK
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Figure B.45: Correlation of RG DSC and Clinician derived TBR
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Figure B.46: Correlation of WT DSC and Clinician derived MTV
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Figure B.47: Correlation of WT DSC and Clinician derived SUVPEAK
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Figure B.48: Correlation of WT DSC and Clinician derived TBR
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Appendix C
Investigation into the inclusion
of morphological data in
machine learned training
models data
C.1 Training models DSC
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Figure C.1: DSC of ATLAAS using the parameters NI, TBR and MTV and
Area Density (Axis Aligned) on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.2: DSC of ATLAAS using the parameters NI, TBR and MTV and
Area Density (Convex Hull) on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.3: DSC of ATLAAS using the parameters NI, TBR and MTV and
Area Density (Enclosing Ellipsoid) on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.4: DSC of ATLAAS using the parameters NI, TBR and MTV and
Asphericity on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.5: Dice similarity coefficient of ATLAAS using the parameters NI,
TBR and MTV and Compactness one on 4, 3, 2 and 1 mm PET validation
scans.
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Figure C.6: DSC of ATLAAS using the parameters NI, TBR and MTV and
Compactness two on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.7: DSC of ATLAAS using the parameters NI, TBR and MTV and
COMShift on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.8: DSC of ATLAAS using the parameters NI, TBR and MTV and
Volume Density (Axis Aligned) on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.9: DSC of ATLAAS using the parameters NI, TBR and MTV and
Volume Density (Convex Hull) on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.10: DSC of ATLAAS using the parameters NI, TBR and MTV and
Volume Density (Enclosing Ellipsoid) on 4, 3, 2 and 1 mm PET validation
scans.
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Figure C.11: DSC of ATLAAS using the parameters NI, TBR and MTV and
Elongation on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.12: DSC of ATLAAS using the parameters NI, TBR and MTV and
Flatness on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.13: DSC of ATLAAS using the parameters NI, TBR and MTV and
Integrated Intensity on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.14: DSC of ATLAAS using the parameters NI, TBR and MTV and
Least Axis Length on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.15: DSC of ATLAAS using the parameters NI, TBR and MTV and
Major Axis Length on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.16: DSC of ATLAAS using the parameters NI, TBR and MTV and
Maximum 3D Diameter on 4, 3, 2 and 1 mm PET validation scans.
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Figure C.17: DSC of ATLAAS using the parameters NI, TBR and MTV and
Minor Axis Length on 4, 3, 2 and 1 mm PET validation scans.
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